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vABSTRACT
A common phenotype observed in most cancers is chromosomal instability.  This
includes both structural and numerical chromosomal aberrations, which can promote
carcinogenesis.  The fusion gene CBFB/MYH11 is created by the structural chromosomal
inversion(16)(p13.1q22), resulting in the fusion protein CBFβ-SMMHC, which blocks
differentiation in hematopoietic progenitor cells.  This mutation alone, however, is not
sufficient for transformation, and at least one additional cooperating mutation is
necessary.
The role of wildtype Cbfb in modulating the oncogenic function of the fusion
protein Cbfβ-SMMHC in mice was examined.  Transgenic mice expressing the fusion
protein, but lacking a wild-type copy of Cbfb, were created to model the effects of these
combined mutations.  It was found that wild-type Cbfb is necessary for maintaining
normal hematopoietic differentiation.  Consequently, complete loss of wild-type Cbfb
accelerates leukemogenesis in Cbfb/MYH11 mice compared to mice expressing both the
fusion and wild-type proteins.  While there is no evidence in human patient samples that
loss of wild-type Cbfb expression cooperates with the fusion protein to cause
transformation, it is apparent from these experiments that wild-type Cbfβ does play a role
in maintaining genomic integrity in the presence of Cbfβ-SMMHC.  Experiments have
also shown that loss of Cbfb leads to accumulation of hematopoietic progenitor cells,
which may acquire additional cooperating mutations.
Not unlike CBFB/MYH11, the human papillomavirus (HPV) E6 and E7 proteins
are not sufficient for cellular transformation.  Instead, high risk HPV E7 causes numerical
chromosomal aberrations, which can lead to accumulation of additional cooperating
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mutations.  Expression of HPV-16 E7 and subsequent downregulation of the
retinoblastoma protein (Rb) has been shown to induce polyploidy in human
keratinocytes.   Polyploidy predisposes cells to aneuploidy and can eventually lead to
transformation in HPV positive cells.
There are several possible mechanisms through which E7 may lead to
polyploidization, including abrogation of the spindle assembly checkpoint, cleavage
failure, abrogation of the postmitotic checkpoint, and re-replication.  Rb-defective mouse
and human cells were found to undergo normal mitosis and complete cytokinesis.
Furthermore, DNA re-replication was not found to be a major mechanism to
polyploidization in HPV-E7 cells upon microtubule disruption.  Interestingly, upon
prolonged mitotic arrest, cells were found to adapt to the spindle assembly checkpoint
and halt in a G1-like state with 4C DNA content.  This post-mitotic checkpoint is
abrogated by E7-induced Rb-downregulation leading to S-phase induction and
polyploidy.
This dissertation explores two examples of the multi-step pathway in human
cancers.  While certain genes or genetic mutations are often characteristic of specific
cancers, those mutations are often not sufficient for transformation.  The genetic or
chromosomal abnormalities that they produce often stimulate the additional mutations
necessary for oncogenesis.  The studies with Cbfb/MYH11 and HPV E7 further exemplify
the significance of numerical and structural chromosomal aberrations in multi-step
carcinogenesis.
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CHAPTER I
GENERAL INTRODUCTION
21.1 Chromosomal Instability and Cancer.  Cancer is a multistep process involving
mutations in multiple genes and genetic pathways usually affecting two major classes of
cancer-related genes: oncogenes and tumor suppressors.  Oncogenes promote neoplastic
transformation when they are aberrantly activated.  For example, activation of an
oncogene may result in a cellular proliferative advantage.  Conversely, tumor suppressors
normally function to inhibit transformation, and mutations in them often negate their
normal protective function.  Whereas oncogenes are often genetically dominant,
mutations in tumor suppressors are often recessive.  Cells containing both types of these
mutations have a significant growth advantage and may expand to form a clonal pre-
malignant neoplasm.  Additional somatic mutations are necessary for full transformation
and progression to malignant and metastatic cancers (reviewed in (Hahn & Weinberg,
2002)).
There are over 100 types of cancers recognized and classified, including both
solid tumors and cancers of the blood (leukemias).  Most cancers exhibit phenotypic
hallmarks that result in genetic mutations in common pathways necessary for
transformation.  Normal cells undergo senescence or apoptosis after a finite number of
divisions, however, transformed cells become immortalized and have unlimited
replicative ability (Newbold & Overell, 1983).  Immortalization and transformation is
often accomplished through mutation of genes that confer proliferative or anti-apoptotic
advantages.  Cancerous cells are also less responsive to their environment.  Most
transformed cells exhibit a loss of contact inhibition and do not halt proliferation when
touching neighboring cells (Holley & Kiernan, 1968).  Other hallmarks include loss of
growth factor dependence (Cross & Dexter, 1991) and an ability to grow in the absence
3of anchorage (Reddig & Juliano, 2005).  A more recently acknowledged hallmark of
human cancers is chromosomal instability (CIN), which may accelerate the activation of
proto-oncogenes, increase the accumulation of mutations in tumor suppressor genes,
and/or facilitate resistance to apoptosis (reviewed in (Lengauer et al, 1998)).  CIN may be
caused by subtle point mutations or drastic chromosomal aberrations, such as
translocations between chromosomes.  These more severe mutations can be classified
into numerical or structural chromosomal changes.
Numerical chromosomal abnormalities occur when there are changes in the
overall number of chromosomes, such as polyploidy and aneuploidy, the state of having
an even multiple or an abnormal multiple of chromosomes, respectively. Cells with these
types of chromosomal aberrations often produce more mutations as a result of the
changing genomic state of the cell (Andreassen et al, 2001; Meraldi et al, 2002).  For
example, in pre-cancerous Barrett’s esophagus cells, polyploidy subsequently leads to
aneuploidy, which has been shown to be an early event in multi-step carcinogenesis
(Galipeau et al, 1996).
Structural changes are specific rearrangements of chromosomes including
deletions, inversions, and translocations. For example, the first structural chromosomal
rearrangements to be associated with a specific disease is the translocation t(9;22) also
called the Philadelphia chromosome, which codes for the fusion gene BCR-ABL (Nowell
& Hungerford, 1960).  The dimerization activity of the Bcr protein results in constitutive
activation of the Abl tyrosine kinase, which creates an oncogene found in all patients
with chronic myeloid leukemia (CML) (reviewed in (Barnes & Melo, 2002). Structural
4chromosomal aberrations are primarily found in leukemic cells, and many subtypes of
leukemia can be classified according to the resulting chromosomal rearrangement.
1.2.1 Acute Myeloid Leukemia.  Hematopoiesis is the process by which red and white
blood cells are formed in the bone marrow.  Proper production of these cells is necessary
to defend against infection, protect against injury, and to deliver oxygen.  Cells are
formed from pluripotent hematopoietic progenitor stem cells through mechanisms of
proliferation and differentiation.  Cytokine signaling pathways are important for
maintaining proper expansion of the blood cells, while transcription factors are important
in regulating the differentiation potential of these cells.  Tight control over both these
processes is important for hematopoiesis and prevention of leukemia.  A block in
differentiation prevents proper expansion of necessary blood and immune cells
throughout the body.  An increase in proliferation or a lack of apoptosis increases the
amount of immature hematopoietic cells in the body, which may preclude any normal
blood cells from carrying out their normal processes.
When a progenitor cell acquires a mutation that results in a block in
differentiation, and the same cell also acquires a proliferative or survival advantage, that
cell may become transformed.  This pre-leukemic cell can then clonally expand and form
a leukemic population.  Therefore, mutations in both of the differentiation and
proliferation pathways are necessary in order to develop leukemia (Speck & Gilliland,
2002).  Based on these observations, Gilliland (2001) has proposed a “two-hit model,”
where two disparate but cooperating mutations are necessary for leukemogenesis.  A
“class I” mutation confers a growth advantage to hematopoietic progenitors, including an
5increase in proliferation, self-renewal, or anti-apoptotic function, while a “class II”
mutation interferes with hematopoietic differentiation (Gilliland, 2001).  The labels “I”
and “II” do not imply a temporal order for these mutations, and it is currently unknown as
to whether the order of accumulation is important for leukemogenesis.
Clinical analysis of human leukemia patients has shown that a large percentage
have non-random chromosomal aberrations, including translocations, inversions, and
deletions (Look, 1997).  CML is exclusively associated with the aforementioned
Philadelphia chromosome t(9;22) (Barnes & Melo, 2002).  Genomic aberrations have
been detected in over 80% of chronic lymphoid leukemia (CLL) patients including the
13q14, 11q, and 17p deletions (Stilgenbauer et al, 2002).  Approximately 65% of acute
leukemias contain disease-specific chromosomal translocations.  Most of the structural
rearrangements in the acute leukemias create oncogenic fusion proteins mainly involving
hematopoietic transcription factors important for hematopoietic differentiation and are
usually classified as Class II mutations.  The cooperating Class I mutations are most often
found in oncogenes or tumor suppressors important in apoptosis, proliferation, or the cell
cycle.
The acute leukemias include acute myeloid leukemia (AML) and acute
lymphoblastic leukemia (ALL), which affect the myeloid and lymphoid lineages
respectively.  The French-American-British (FAB) system of classification divides AML
into 8 subclasses (M0-M7) based on morphology, immunophenotyping, and
histochemical staining.  The most commonly targeted transcription factor in human
AML, affecting 24%, is the Core-Binding Factor (CBF) (Look, 1997) (Figure 1.1).
6Figure 1.1.  Distribution of chromosomal aberrations in acute leukemias.  Acute
leukemias are often characterized by distinct chromosomal aberrations including
translocations and inversions.  The CBF transcription factor is affected in nearly a quarter
of acute myeloid leukemias including the fusions AML1/ETO and CBFB/MYH11.
Figure 1.1
(Look 1997)
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81.2.2 Core Binding Factor.  CBF is a heterodimeric transcription factor important in
hematopoietic differentiation.  The dimer is comprised of one of three DNA-binding α-
subunits (RUNX1, RUNX2, or RUNX3) and a β-subunit (CBFβ)1.  The RUNX subunits
bind the DNA at a specific TGYGGT consensus binding site through the Runt homology
domain, which is very similar to the Drosophila Runt protein (Bae et al, 1994).  The
RUNX subunit also binds to CBFβ through the Runt domain, which causes a
conformational change that increases the RUNX binding affinity to DNA (Goger et al,
1999).  The RUNX subunit is found primarily in the nucleus (Kanno et al, 1998).
Because CBFβ is mostly cytoplasmic (Brown et al, 1995), the β-subunit must be bound
to the α-subunit in order to enter the nucleus and act as the CBF transcription factor.
Studies in the mouse have shown that the Cbfβ:Runx1 heterodimer acts as an
important regulator of definitive hematopoiesis in embryos, the process through which
the fetal yolk sac and subsequently the fetal liver form the erythroid and myeloid lineages
of hematopoietic cells in the embryo (Castilla et al, 1996; Okuda et al, 1996; Sasaki et al,
1996; Wang et al, 1996b).  The Cbfβ:Runx1 heterodimer also regulates  myeloid and
lymphoid differentiation in adults (Ichikawa et al, 2004).  The CBF complex regulates
these processes through transcription of genes such as T-cell receptor β (TCRβ) and
interleukin-3 (IL-3) (Cameron et al, 1994; Prosser et al, 1992).  The Cbfβ:Runx2
heterodimer plays an essential role in osteogenesis (Komori et al, 1997), and the
Cbfb:Runx3 heterodimer is involved in the neurogenesis of the dorsal root ganglia, T-cell
differentiation, and maintenance of the gastric epithelium (Ito & Miyazono, 2003).
                                                 
1 Other names for the α and β subunits of CBF: RUNX1= AML1, CBFA2, PEBP2αB.
RUNX2= AML3, CBFA1, PEBP2αA.  RUNX3= AML2, CBFA3, PEBP2αC.  CBFB=
PEBP2β.
9As previously mentioned, studies in the mouse have determined that both Cbfb
and Runx1 are important in definitive hematopoiesis, since Cbfb-/- or Runx1-/- embryos fail
to develop embryonic definitive hematopoiesis and die at midgestation, e11.5-e13.5, due
to hemorrhaging in the central nervous system (Okuda et al, 1996; Sasaki et al, 1996;
Wang et al, 1996a; Wang et al, 1996b).  This phenotype was rescued in Cbfb-/- mice by
expressing Cbfb from the hematopoietic specific promoters Tie2 or GATA1 (Miller et al,
2002; Yoshida et al, 2002), further underlining the key role of Cbfb during hematopoietic
differentiation. It has also been suggested that Cbfβ is essential for the generation of
hematopoietic stem and progenitor cells and that decreased Cbfβ expression may lead to
an accumulation of these progenitor cells as represented by an increase in c-kit+ and/or
Sca1+ progenitor cells (Kundu & Liu, 2003).
Mutations affecting CBF, including point mutations, translocations, and
inversions, are also present in 30% of all human leukemias (Lutterbach et al, 1999;
Roulston et al, 1998; Speck & Terryl, 1995), primarily AML and ALL, and also
myelodysplasia, abnormal formation of bone marrow cells. However, while point
mutations in RUNX1 have been associated with AML (Preudhomme et al, 2000; Reilly,
2005), a correlation between point mutations in CBFβ and AML has not been established
(Leroy et al, 2002). The translocation t(8;21)(q22;q22), creating the fusion gene
RUNX1/ETO, and the inversion inv(16)(p13;q22), creating the fusion gene
CBFB/MYH11, are the most common chromosomal aberrations in AML (Figure 1.1)
(Look, 1997).
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1.2.3 CBFB/MYH11.  The most common form of the inv16 CBFB/MYH11 mutation
breaks and joins the first five exons of CBFB, including the complete RUNX
heterodimerization domain, with the C-terminal half of MYH11, encoding the smooth
muscle myosin heavy chain (SMMHC) protein (Liu et al, 1993).  The resulting CBFβ-
SMMHC fusion protein can multimerize through the SMMHC multimerization domain
and retains its ability to bind to the RUNX subunit (Figure 1.2) (Liu et al, 1993).
The inv16 chormosomal aberration is tightly associated with AML M4Eo, which
is classified as having an increased amount of myeloblasts and abnormal eosinophils in
the peripheral blood.  Inv16 AML patients also show a significant increase in their white
blood cell count and splenomegaly, an enlarged spleen, resulting from the increased
difficulty in filtering the increased amount of myeloblasts in the blood.
In order to study the fusion protein, a knock-in mouse model was created (Figure
1.3A).  Like the Cbfb-/- and Runx1-/- embryos, these heterozygous mice also died at
midgestation due to failure of definitive hematopoiesis (Castilla et al, 1996; Okuda et al,
1996; Sasaki et al, 1996; Wang et al, 1996a; Wang et al, 1996b).  Because only one allele
of the fusion gene was necessary for this phenotype, this suggests that Cbfβ-SMMHC is a
dominant inhibitor of CBF function.
There are two major models that attempt to explain the dominant CBFβ-SMMHC
function over wildtype CBFβ.  The sequestration model proposes that the fusion protein
binds to the Runx subunit and sequesters it in the cytoplasm, either by forming multimers
or by binding to the actin filaments (Adya et al, 1998; Kanno et al, 1998).  The repression
model proposes that the fusion protein is able to suppress CBF transcription through
11
Figure 1.2.  The CBFB/MYH11 fusion gene results from an inversion of chromosome
16.  The fusion protein CBFβ-SMMHC retains the CBFα heterodimerization domain and
the SMMHC coiled-coil multimerization region.
MYH11
CBFB
Figure 1.2
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Figure 1.3.  Cbfb/MYH11 knock-in and conditional knock-in mouse targeting
scheme.  A. The human CBFB cDNA for exon 5 fused to MYH11 was knocked-into the
mouse Cbfb gene after exon 4. B.  The human CBFB cDNA for exons 5 and 6 flanked by
LoxP sites was inserted into the knock-in gene.  Transcription of this gene results in full-
length wild-type Cbfβ protein expression.  Upon excision of the loxP sites, the fusion
gene Cbfb/MYH11 is transcribed.
(Kuo et al, 2006)
(Castilla et al, 1996)
Figure 1.3
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interaction with the repression domain at its C-terminal end, which can bind to AML-1B
and recruit corepressors (i.e. mSin3A) to the DNA (Lutterbach et al, 1999).
Isothermal titration calorimetry results suggest that the CBFβ-SMMHC protein
disrupts Runx1-CBFβ function by binding to the Runt domain of Runx1 with a higher
affinity than wild-type CBFβ (Lukasik et al, 2002).  Both CBFβ and SMMHC are able to
bind to the Runt domain, and this simultaneous interaction is what causes the higher
binding affinity.  However, in the presence of DNA, CBFβ and CBFβ-SMMHC bind to
the Runt domain with similar affinities.  These results provide some explanations for both
dominance models.  First, the data suggest that the CBFβ-SMMHC fusion protein could
sequester Runx1 in the cytoplasm and prevent translocation to the nucleus for CBF
transcription.  This calorimetry data also supports the repression model by explaining that
the Runx subunit could bind to the fusion protein preferentially and result in repression
rather than bind to CBFβ and result in normal transcription (Lukasik et al, 2002).
1.2.4 Additional Mutations.  Because the knock-in mice are embryonic lethal, chimeras
and a conditional knock-in mouse model were developed to study the fusion gene in
adults.  The targeting scheme for the generation of the conditional knock-in mice uses the
Cre-Lox system and is depicted in Figure 1.3B.  In this system, Cbfb sequences for exons
5 and 6 flanked by loxP sites are inserted into intron 4 of Cbfb before the knock-in
sequence.  This design allows for the full length wild-type Cbfb transcript to be expressed
in developing mice.  These mice were then crossed with Mx1-Cre mice, where Cre is
expressed from the interferon responsive Mx1 promoter.  Upon addition of polyinosinic-
polycytidylic acid (pIpC), which mimics double stranded RNA, the interferon cascade is
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activated and Cre is expressed from the Mx1/Cre transgene.  This causes excision of the
sequences between the loxP sites, exons 5 and 6, and the fusion gene is once again
expressed.
Using chimeras and conditional knock-in mice, it has been shown that the fusion
protein impairs adult hematopoiesis by causing a partial differentiation block of the
myeloid and lymphoid lineages (Castilla et al, 1999; Castilla et al, 1996; Kuo et al, 2006).
However, induction of Cbfβ-SMMHC expression or Runx1-loss in adult bone marrow
(BM) does not seem to affect the maintenance of long-term hematopoietic stem cells
(HSC) (Growney et al, 2005; Ichikawa et al, 2004; Kuo et al, 2006).
Several lines of evidence suggest that Cbfβ-SMMHC may exert an incomplete
block of CBF function. First, ectopic expression of the fusion protein in embryonic stem
cells expressing one or both copies of Cbfb does not inhibit differentiation in vitro (Miller
et al, 2001).  Second, although RUNX1 is important for stem cell emergence, Cbfb+/MYH11
knock-in hematopoietic stem cells expressing Cbfβ-SMMHC still persist in the BM of
chimeras (Castilla et al, 1999).  Last, retroviral insertional mutagenesis in Cbfb-MYH11
knock-in chimeras identified common insertions in the Runx2 gene (Castilla et al, 2004),
suggesting that Cbfβ-SMMHC leukemic function is affected by levels of Runx proteins.
 The chimera and conditional knock-in studies have also shown that while the
fusion protein is necessary for leukemogenesis, it is not sufficient, and additional genetic
mutations are required for full transformation in these mice (Castilla et al, 1999; Castilla
et al, 2004; Kuo et al, 2006).  The fusion gene Cbfb/MYH11 acts as a Class II mutation
and therefore requires a cooperating Class I mutation.  Cbfβ-SMMHC expression reduces
17
HSC function by inhibiting multilineage repopulation (blocking differentiation) and
creating a myeloid progenitor predisposed to leukemia development. (Figure 1.4)
There are several methods of generating and screening for cooperating Class I
mutations in Cbfb/MYH11 mice.  A common method to generate many mutations is
through addition of N-ethyl-N-nitrosourea (ENU), a potent DNA alkylating agent.
Although this results in quick onset of leukemia, it is difficult to map the potential
contributing mutations.  Another more practical method is retroviral insertional
mutagenesis (RIM), which was performed in our lab by infecting Cbfb/MYH11 mice with
the amphotropic murine leukemia virus (MLV) strain 4070A.  The virus is able to insert
itself throughout the genome and induce misexpression of genes in one of several ways.
The virus may integrate upstream of a gene’s transcription initiation site or in the 5’UTR
where the strong viral promoter and enhancer sequences present in the long terminal
repeat (LTR) would cause promoter activation and upregulation of the gene, most likely
an oncogene.  Alternatively, the virus may insert in the coding region of a gene resulting
in a truncated or disrupted protein, such as a tumor suppressor.  In those mice that then
develop leukemia, inverse PCR can be used to map the locations of these insertions,
thereby determining the potential disruption that acted as a cooperating class I mutation.
Finally, a candidate based approach can be used where mutations in common oncogenes
or tumor suppressors are tested for cooperation with the Cbfb/MYH11 fusion to cause
leukemia.
Class I mutations that have been shown to correlate with Cbfb/MYH11-induced
leukemias include activating mutations in the receptor tyrosine kinases, c-KIT and FLT3,
and the RAS genes, specifically N-RAS and K-RAS (Reilly, 2005).  However, these
18
Figure 1.4.  HSCs require a Class I and Class II mutation for leukemogenesis.  The
presence of the fusion protein Cbfβ-SMMHC blocks differentiation, however an
additional Class I mutation is required for acute myeloid leukemia progression.
Differentiation block
Class I mutation:
Proliferative or survival mutation
Acute Myeloid Leukemia
Hematopoietic
Stem cell / progenitor
Self-renewal
Class II mutation:
Cbfb-MYH11
Figure 1.4
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account for less than half of all human CBFB/MYH11 AMLs.  Evidence has also
suggested other potential “second hits.”  These include inactivation of tumor suppressors
including p53 or activation of oncogenes such as Plag1 and PlagL2 (Castilla et al, 2004).
Landrette et al have confirmed that these oncogenes, aberrantly activated, do indeed
cooperate with Cbfb/MYH11 to form leukemia (Landrette et al, 2005). Also, mutation of
the Runx2 gene has been proposed as a potential cooperating mutation with Cbfb/MYH11
from RIM where the virus caused truncated forms of RUNX2 to be expressed with a
putative dominant negative function (Castilla et al, 2004).
Chapter II of this dissertation tests the hypothesis that Cbfβ modulates the effect
of Cbfβ-SMMHC in the BM hematopoietic progenitors and leukemogenesis.
Specifically, the study explores whether Cbfβ-SMMHC, a Class II mutation, causes an
incomplete differentiation block dependent on Cbfβ levels, and whether the complete
lack of remaining wild-type Cbfβ leads to an acceleration of leukemia compared to those
mice with the presence of the fusion protein and wild-type Cbfβ.  To test this hypothesis,
adult myeloid differentiation and leukemia development in mice with a conditional
Cbfb/MYH11 knock-in allele and a Cbfb null allele was studied.
1.3.1 Human papillomavirus.  Introduction of viral oncogenes may also act as
cooperating Class I mutations.  For example, the HPV-16 E7 oncogene has been shown
to cooperate with Cbfβ-SMMHC to induce AML in mice.  It is thought that E7 does this
by accelerating the progression from G1 to S by degrading pRb (Yang et al, 2002).
Papillomaviruses (Figure 1.5A) are small DNA viruses can only infect replicating
epithelial cells.  Only those cells at the basal epithelium are replicating, and HPV
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Figure 1.5.  Human Papillomavirus.  A. Image of HPV capsid proteins.  B. The HPV
genome has 8 open reading frames.  These genes code for early (E) non-structural
regulatory proteins and late (L) structural capsid proteins.
Figure 1.5
A
(Zheng and Baker, 2006)
B
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particles reach this lower stratum through micro-lesions and tears in the epithelium.  As
the basal cells migrate towards the surface, they terminally differentiate and exit the cell
cycle.  However HPV, like other DNA viruses, must utilize the host cell’s replication
machinery as it progresses through S-phase.  Therefore HPV has evolved proteins that
promote cell cycle progression in differentiated cells.  As these cells migrate towards the
surface, the viral particles are encapsulated and the resulting virions are released to infect
other cells (Figure 1.6, reviewed in (Fehrmann & Laimins, 2003).
The HPV genome is a circular double stranded DNA genome consisting of
approximately 8 kb. There are more than 100 types of HPV identified, and they infect the
genital tract, head, neck, hands, and feet.  Those that infect the genital tract are divided
into high-risk and low-risk based upon their ability to cause malignant versus benign
lesions, respectively.  Low-risk HPVs (e.g. types 6 and 11) are primarily associated with
benign lesions such as genital warts.  High-risk HPVs (e.g. types 16, 18, and 31) are
associated with lesions that can lead to high-grade cervical intraepithelial neoplasia and,
ultimately, to cervical carcinoma.  Cervical cancer is one of the leading causes of cancer
death in women worldwide (zur Hausen, 2002), and greater than 99% of all cervical
cancers are HPV positive (Walboomers et al, 1999).  Worldwide, approximately 493,000
new cases are diagnosed each year, and over 273,000 women die from invasive cervical
cancer each year (National Cervical Cancer Coalition).
In addition to cervical cancers, more than 50% of other anogenital cancers and
25% of oral/esophageal cancers are HPV positive (reviewed in (zur Hausen, 2002)).
Although tobacco and alcohol are responsible for most head and neck squamous cell
carcinomas (HNSCC), there is evidence for a causal association between HPV and a
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Figure 1.6. HPV Pathology.  HPV infects the basal epithelial layer.  As the cells migrate
towards the surface, the HPV genome is replicated and encapsulated, and the viral
particles are released.
Basal epithelium
Normal
Viral particles
HPV Infection
Figure 1.6
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subset of HNSCCs (Gillison et al, 2000). Also, HPV-associated cervical and anogenital
cancers and HNSCCs are frequently found among HIV-infected individuals because of
their suppressed immune system (reviewed in (Del Mistro & Chieco Bianchi, 2001).
Their compromised immune systems make their cancers difficult to treat, therefore
understanding the precursors of HPV-induced cancers is fundamentally important.
Progress has recently been made in the prevention of HPV-associated diseases in
the form of a preventative vaccine against the most harmful types of the virus.  In the
summer of 2006, the first prophylactic vaccine was approved for prevention of HPV
infection.  Gardasil® (Merck & Co) is a quadrivalent vaccine which contains
recombinant virus-like particles assembled from the L1 capsid proteins of four HPV
types- 16 and 18, which together cause 70% of cervical cancers, and 6 and 11, which
together cause 90% of genital warts (Villa et al, 2005).  Because these particles do not
contain HPV DNA, they are not harmful.  However the multiple capsid proteins are able
to trigger an antibody response in the host to prevent against future HPV-6, 11, 16, or 18
infection.
  Unfortunately, this vaccine is not a cure; it does not alleviate pre-existing
infections.  Also, this vaccine only works on 4 types of HPV, albeit the most potentially
harmful, whereas there are over 30 types that are able to infect the genital epithelium.
Furthermore, while trials have been promising, the total efficacy in preventing cervical
cancer has not been proven over a long period of time (Hymel, 2006). Lastly,
vaccinations do not work well in immunocompromised individuals, such as AIDS
patients, who are more at risk than the average population for acquiring an HPV
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infection.  Therefore, elucidating the mechanism behind HPV transformation is still
important for the development of therapies against HPV-associated malignancies.
The HPV genome (Figure 1.5B) contains 8 open reading frames, with their gene
products divided into two groups, early (E) non-structural regulatory proteins and late (L)
structural capsid proteins.  The E1 helicase is essential for viral DNA replication
(reviewed in (Doorbar, 2006)).  E1 cooperates with the E2 transcription factor, which is
essential not just for viral DNA replication, but also genome segregation and regulation
of early transcription, including that of E6 and E7 (reviewed in (Doorbar, 2006)).  The
role of E4 is still not fully established, but it has been suggested to play a role in viral late
functions (Peh et al, 2004).  E5 encodes a membrane protein whose function is unknown
but appears to have some transforming activity and is therefore a possible oncogene
(reviewed in (Doorbar, 2006).  The main transforming properties of high-risk HPVs
reside primarily in the E6 and E7 oncogenes and will be discussed further.  The two late
genes L1 and L2 encode capsid proteins and are important in viral efficiency (reviewed in
(Doorbar, 2006)).
1.3.2 E6 and E7 oncoproteins.  Because of the importance of the p53 and
retinoblastoma (Rb) tumor suppressors in maintaining cellular homeostasis, most DNA
tumor viruses have evolved proteins that are able to bind to and inactivate them.  For
example, Adenovirus E1A and HPV E7 are able to bind to and inhibit Rb.  This prevents
Rb’s interaction with E2F, leaving the E2F transcription factor free to activate S-phase
proteins thereby causing progression of the cell cycle.  Proteins from these same viruses,
Adenovirus E1B55k and HPV E6, are able to bind and inhibit p53 function as well.  The
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Simian Virus 40 (SV40) Large T protein is able to bind and inactivate both Rb and p53.
In most of these viruses, including HPV E6 and E7, the proteins not only facilitate
replication of the virus, but often lead to transformation of the host cell as well.
The E6 protein is approximately 150 amino acids and contains two zinc-binding
domains.  The oncogenic activities of E6 have been demonstrated in multiple biological
assays, including immortalization of primary cells through activation of telomerase,
transformation of established mouse fibroblasts, resistance to terminal differentiation of
human keratinocytes, tumorigenesis in animals, modulation of apoptosis, and abrogation
of cell cycle checkpoints (reviewed in (Fan & Chen, 2004; Mantovani & Banks, 2001;
Rapp & Chen, 1998).  The most prominent activity associated with E6 is its ability to
bind and cause degradation of the p53 tumor suppressor.  E6 first binds to the ubiquitin
ligase E6-associated protein (E6-AP), and together they bind p53 as a complex
(Huibregtse et al, 1993).  E6-AP is then able to ubiquitinate p53, which marks p53 for
proteolysis by the proteasome (Scheffner et al, 1993). High-risk HPV E6 proteins are also
able to activate telomerase (Klingelhutz et al, 1996).  These two functions of E6 are
thought to be the major mechanisms through which E6 induces cellular transformation
(Scheffner & Whitaker, 2003). Low-risk E6 proteins are only able to bind p53 and cannot
target it for degradation.  E6 also has functions independent of inactivating p53, including
binding with and causing degradation of additional cellular proteins such as the
proapoptotic protein Bak (Jackson et al, 2000), the DNA repair protein MGMT
(Srivenugopal & Ali-Osman, 2002), and the transcription factor Myc (Gross-Mesilaty et
al, 1998).
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E7 is a nuclear protein of approximately 100 amino acids.  Its amino terminus
contains sequence homology to conserved region 1 (CR1) and CR2 of adenovirus E1A
and SV40 (Barbosa et al, 1990; Phelps et al, 1988).  The carboxy terminus contains a
zinc-binding domain where E7 can dimerize/multimerize (Clemens et al, 1995).  While
E7 alone is able to immortalize human keratinocytes, the additional expression of E6
greatly enhances the frequency at which this occurs (Bedell et al, 1989; Halbert et al,
1991).
The most reported activity of E7 is its association with members of the
retinoblastoma (Rb) tumor suppressor family, including p110Rb (Rb), p107, and p130
(Figure 1.7) (Davies et al, 1993; Dyson et al, 1989).  Rb is one of the key regulators of S-
phase progression through its interaction with the E2F family of transcription factors.
Normally, Rb is considered active when hypophosphorylated and is then able to bind E2F
transcription factors and thereby repress transcription of genes containing E2F promoter
sites.  Most of these genes are either required for the G1 to S phase transition or for S-
phase replication and are therefore transcribed in a cell cycle dependent manner. (La
Thangue, 1994; Slansky & Farnham, 1996)  When Rb is hyperphosphorylated, it is
unable to bind to E2F and the cell progresses through S-phase.  E7 is able to bind Rb in
its hypophosphorylated state (Dyson et al, 1989), which blocks binding to E2F, again
promoting cell cycle progression through S-phase (Chellappan et al, 1992).  The E7
protein from high and low risk types of HPV are able to bind to Rb, however, once bound
to Rb, high-risk HPV-E7s are able to induce ubiquitin-mediated degradation of Rb
(Giarre et al, 2001).
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Figure 1.7.  E7 expression results in down-regulation of Rb. When Rb is
hyperphosphorylated by cdk/cyclinD complex, it is unable to bind to E2F and the cell
progresses through S-phase.  E7 is able to bind to Rb in its hypophosphorylated state,
which blocks binding to E2F, again promoting cell cycle progression through S-phase.
E7 is also able to inhibit function of the CKIs p21 and p27, which allows for
phosphorylation of Rb.
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While Rb may be E7’s most common and most studied interacting partner, E7 has
other interactions as well.  Many of these interactions induce cell cycle progression and
include: abrogating the inhibitory functions of cyclin-dependent kinase inhibitors p21
(Funk et al, 1997; Jones et al, 1997) and p27 (Zerfass-Thome et al, 1996); increasing the
protein levels of the tyrosine phosphatase cdc25A (Katich et al, 2001); activating E2F2
transcription through binding to class I histone deacetylases (HDACs) (Longworth et al,
2005); degrading Rb through binding of the S4 subunit of the 26S proteasome
(Berezutskaya & Bagchi, 1997).
Expression of both high-risk HPV E6 and E7 proteins is sufficient to immortalize
primary human epithelial cells, however they are unable to induce transformation (Fan et
al, 2005).  Instead, it is proposed that the centrosome abnormalities, aberrant spindle pole
formation, and genomic instability caused by E6 and E7 result in cells accumulating
additional genomic aberrations necessary for malignant transformation. (Duensing et al,
2000; Duensing & Munger, 2002b). The sustained expression of E6 and E7 also appears
to be essential for the maintenance of the transformed state of HPV-positive cells
(Alvarez-Salas et al, 1998).  Low-risk HPV types are unable to immortalize primary cells
(Thomas et al, 2001).
Initially, integration of the viral genome, specifically in the E2 coding region, into
the host genome was thought to be necessary for transformation, because of E2’s ability
to regulate E6 and E7 (Schwarz et al, 1985; Stoler et al, 1992).  However, it has now been
shown in studies of cervical cancer patients that approximately one-third of patients with
malignant cervical lesions maintain an episomal HPV genome (Arias-Pulido et al, 2006;
Cheung et al, 2006).  Real-time PCR analysis showed that the amount of E7 in cervical
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lesions is greatly increased compared to normal cells, although when normalized to viral
content the number was not significant (Cheung et al, 2006); there was more E7 because
there was more virus being produced.  It has also been shown that E2 often acquires
deletions that may inhibit its function (Arias-Pulido et al, 2006).  All of these results
suggest that E2 downregulation through integration or otherwise may not be necessary
for increased E7 expression.  Therefore, integration of the HPV genome may not be
necessary for transformation.
In most cancer cells, potential initial causes of genomic instability are DNA
damage and telomere shortening, both of which are found to occur in E6 and E7
expressing cells (Duensing & Munger, 2002b).  Expression of HPV-16 E6 and/or E7 is
associated with both structural and numerical chromosomal alterations (Coursen et al,
1997; Reznikoff et al, 1994; White et al, 1994). In normal human keratinocytes,
expression of HPV-16 E7 rapidly induces abnormal centrosome duplication (within 48
h), whereas E6 has no immediate effect and takes longer to show centrosome
abnormalities (Duensing et al, 2000). These HPV-16 E7-induced centrosome
abnormalities represent an early event during neoplastic progression (Duensing et al,
2001).  The ability of E7 to induce abnormal centrosome duplication is independent from
its ability to degrade Rb or other pocket proteins (Duensing & Munger, 2003b).
However, disregulation of cdk2 may contribute to increased centrosome duplication
(Duensing et al, 2000), although lack of cdk2 does not seem to impede duplication (Tetsu
& McCormick, 2003).  Experiments involving both genetic and pharmacological cell
cycle inhibitors suggest that while E7 may play a direct role in centrosome duplication,
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the ability of E7 to induce centrosome duplication errors is connected to its ability to
deregulate the cell cycle (Duensing & Munger, 2002a).
HPV-16 E7 and E6 separately expressed in mice under the control of an estrogen
sensitive cervical cell specific promoter (K14) cause similar amounts of centrosome
duplication/abnormalities.  However, only those mice expressing E7 developed tumors,
whereas the E6-expressing mice did not (Riley et al, 2003).  Because the E6 and the E7
mice had similar amounts of centrosome duplication, but only the E7 mice developed
tumors, this suggests that centrosome abnormalities alone may not be sufficient for
transformation and that E7 has other cellular effects that lead to tumorigenesis.
Telomere shortening could lead to both structural and chromosomal instability
(Gisselsson et al, 2002) and occurs in precursor lesions during cervical carcinogenesis
(Zhang et al, 2004). It was also shown that telomere shortening was the primary cause of
anaphase bridging as well as lagging chromosomes in colorectal cancer cells (Stewenius
et al, 2005).  Anaphase bridging is known to trigger complex rearrangements of
chromosome structure (Stewenius et al, 2005), and is a phenomenon also observed in
cervical intraepithelial neoplasia and cervical carcinoma (Therman et al, 1984).  In E6 or
E7 expressing primary human keratinocytes (PHKs), anaphase bridging correlates with
metaphase lagging and structural chromosomal rearrangements (Duensing & Munger,
2002b).  Expression of HPV-16 E7 alone was also associated with an increased number
of cells exhibiting nuclear foci of phosphorylated histone H2AX as well as activation of
cell cycle checkpoints triggered by DNA repair (Duensing & Munger, 2002b).
It has repeatedly been shown that expression of HPV-16 E6 and/or E7 induces
polyploidy in both primary human fibroblasts and foreskin keratinocytes upon
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microtubule disruption (Di Leonardo et al, 1997; Filatov et al, 1998; Khan & Wahl, 1998;
Patel et al, 2004; Thomas & Laimins, 1998).  However, E6 induces polyploidy more
efficiently in the presence of E7 or in the context of HPV genome (Thomas & Laimins,
1998).  Previous studies have explored the cellular mechanism through which this
polyploidy was formed in HPV-16 E6 expressing cells (Liu et al, 2007).
1.3.3 Polyploidy and aneuploidy. Few women infected with a high-risk HPV type
develop cervical cancer, and those that do usually have a long latency.  Both of these
observations suggest that presence of the HPV genome alone, specifically E6 and E7, is
not sufficient for carcinogenesis.  Rather, the CIN caused by these two oncogenes
predisposes accumulation of additional genetic changes leading to transformation.
As previously mentioned, an important hallmark of human cancers, specifically
those of epithelial origin, is CIN (Klausner, 2002).  The most common manifestation of
CIN is aneuploidy, the state of having an abnormal number of chromosomes (Edwards &
Munger, 2004; Nasmyth, 2002).  This is common in cancers of epithelial origin
(Klausner, 2002), such as cervical cancers, where it can appear at early stages of cervical
neoplasia (Duensing & Munger, 2003a; Heselmeyer et al, 1996).  Several studies have
also demonstrated that aneuploidy can originate from a polyploidy intermediate (Meraldi
et al, 2002; Reid et al, 1996), and may therefore be an early event in multi-step
carcinogenesis (Andreassen et al, 2001; Galipeau et al, 1996; Meraldi et al, 2002).
The cause of CIN is still unclear, although possibilities include mutations that
deregulate telomere maintenance or mitotic integrity.  However, such mutations have not
yet been identified in spontaneous cancers (Duelli et al, 2007).  It is possible that CIN
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could be caused by a transient event, such as polyploidy or aneuploidy, that destabilizes
the genome but does not permanently affect processes like mitosis or proliferation.
HPV-immortalized cell lines frequently acquire numerical chromosome changes
(McCance et al, 1988; Oda et al, 1996; Pei et al, 1994; Solinas-Toldo et al, 1997).  The
HPV oncogenes E6 and E7, which are not sufficient for transformation (Fan & Chen,
2004), render normal human cells, including epithelial stem cells, genomically unstable,
which predisposes them to accumulate additional chromosomal alterations necessary for
malignant transformation (Duensing et al, 2000; Duensing & Munger, 2002b; White et al,
1994). The molecular basis leading to this genomic instability in HPV positive cells is not
fully understood.  In cervical tissue, polyploidy has recently been shown to not only
occur as an early event in cervical carcinogenesis, but to predispose the cells to
aneuploidy (Olaharski et al, 2006).
Polyploidization has also been shown to be a major cause of amplification of
centrosomes (Meraldi et al, 2002), each of which may act as a mitotic spindle pole
(Quintyne et al, 2005), preventing the cells from segregating properly.  If these cells then
complete cytokinesis, the resulting cells will most likely be aneuploid (Edwards &
Munger, 2004). Other recent studies have shown that tetraploid, but not diploid, mouse or
human cells induce tumor formation in mice (Duelli et al, 2007; Fujiwara et al, 2005).
These studies highlight the potential importance of polyploidy in carcinogenesis.
1.3.4 Mechanisms to Polyploidy.  There are several major possibilities through
which polyploidy can be induced (Figure 1.8).  Most of these mechanisms are involved in
improper execution of the cell cycle, including checkpoints that regulate whether the
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Figure 1.8.  Mechanisms to polyploidization.  There are several conflicting
mechanisms through which polyploidy can be induced in E7 expressing cells.  These
include abrogation of the spindle assembly checkpoint followed by cleavage failure,
cleavage failure alone, re-replication, or adaptation to the spindle checkpoint followed by
post-mitotic checkpoint abrogation.
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genome is properly replicated, repaired, and segregated.  It has previously been shown
that defects in checkpoint functions may contribute to genomic and chromosomal
instability [as reviewed in (Hartwell & Kastan, 1994; Paulovich et al, 1997), specifically
polyploidization. There are two checkpoints in eukaryotic cells where defects may lead to
cells acquiring polyploid genomes, including the spindle assembly checkpoint and the
more recently described postmitotic checkpoint (Lanni & Jacks, 1998).
Once in mitosis, the mitotic spindle assembly checkpoint controls the division of
the chromosomes.  Specifically, proper attachment of the microtubules to the
kinetochores and proper alignment of the chromosomes at the metaphase plate are
monitored by the spindle assembly checkpoint.  Activation of the checkpoint delays
chromosome segregation until the mitotic spindle apparatus is correctly assembled
(Musacchio & Hardwick, 2002).  The spindle assembly checkpoint is monitored by the
interplay between two ubiquitin-protein ligases, the anaphase promoting
complex/cyclosome (APC/C) and the Skp1-cullin-F-box (SCF) protein (Vodermaier,
2004).  Although an early study with fibroblasts from p53-/- mouse embryos suggested
that p53 might play a role in the spindle assembly checkpoint (Cross et al, 1995),
subsequent studies demonstrated that p53 is not a key regulator of this checkpoint control
mechanism (Lanni & Jacks, 1998).
The spindle checkpoint is activated until the chromosomes are properly attached
to the spindle and aligned at the metaphase plate.  Cells that do not complete mitosis
often suffer cleavage failure as well.  Therefore, if the spindle checkpoint becomes
abrogated, but the cells still fail to cleave, then the cells will have a 4N DNA content.
These cells may not trigger the post-mitotic checkpoint, and therefore progress through
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the cell cycle becoming polyploid. Cleavage failure may also occur due to disruption of
the microtubule architecture during cytokinesis and abscission.  Once cell division fails,
another round of DNA replication may ensue, which could also result in polyploidy.
Although mutations in spindle assembly checkpoint genes could cause aneuploidy and
predispose cells to cancer (Hanks et al, 2004), loss-of-function mutations in these genes
are rarely observed in human cancers (Hernando et al, 2001).
Cells with intact spindle assembly checkpoint activity that become arrested in
metaphase for prolonged periods of time eventually adapt to the checkpoint and progress
into a G1-like state with 4C DNA content (Lanni & Jacks, 1998; Margolis et al, 2003).
A proposed p53- and pRb-dependent postmitotic checkpoint then prevents the cells from
continuing through G1 and S (Khan & Wahl, 1998; Lanni & Jacks, 1998).  Although
previously referred to as a “tetraploidy” checkpoint (Margolis et al, 2003), it appears that
the structural integrity and dynamics of the microtubules, rather than tetraploidy per se,
triggers cell cycle arrest at this checkpoint (Uetake & Sluder, 2004; Wong & Stearns,
2005).
The postmitotic checkpoint shares many features with the G1 checkpoint,
including high concentrations of p21 and hypophosphorylated Rb during cell cycle arrest
(Borel et al, 2002; Meraldi et al, 2002).  While p53 appears to play a key role in
mediating the postmitotic checkpoint (Andreassen et al, 2001; Di Leonardo et al, 1997;
Lanni & Jacks, 1998; Sablina et al, 1999) and p21 is responsible for at least part of this
p53-mediated postmitotic arrest response (Khan & Wahl, 1998; Lanni & Jacks, 1998;
Stewart et al, 1999), p53-independent, Rb-dependent activities cannot be ruled out.
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Another mechanism that can lead to polyploidization is re-replication, a process
of multiple rounds of DNA replication without an intervening mitosis.  Cells complete S-
phase and enter G2, but then proceed directly into S-phase again.  Re-replication is an
inefficient process to replicate DNA and often yields incomplete copies of the genome
resulting in polyploidy or aneuploidy.
There are many conflicting hypotheses concerning how expression of E7 leads to
polyploidization. Chapter III explores the different mechanisms through which
expression of E7 and subsequent Rb-downregulation leads to polyploidization. Once the
specific mechanism is ascertained, therapies may be developed to prevent accumulation
of polyploidy in E7 expressing and/or Rb-downregulated, untransformed cells.  This may
subsequently prevent the accumulation of numerical genomic aberrations that could
cooperate with E7 and lead to carcinogenesis.
Chapters II and III of this dissertation present two examples of the multi-step
nature of cancer.  While certain genetic mutations or cellular changes may not lead
directly to cancer, such as expression of E7 or the presence of Cbfb/MYH11, they may
increase the likelihood of acquiring mutations that do cause transformation.  First, I
explore how the lack of Cbfb affects Cbfb/MYH11 positive cells.  The presence of the
fusion protein does not lead to transformation on its own, and Cbfb will either act as a
cooperating mutation or will predispose the cell to acquiring other Class I mutations for
leukemogenesis.  One known Cbfb/MYH11 cooperating Class I mutation is the HPV
oncogene E7, which causes acceleration of the progression from G1 to S by degrading
pRb (Yang et al, 2002).  On the other hand, in HPV positive cells, E7 alone is not
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sufficient for transformation. However, E7 does lead to polyploidy, which in turn can
lead to aneuploidy and CIN, and the additional mutations accumulated from CIN may
lead to transformation.  Therefore, in Chapter III of this dissertation I determine the
mechanism that leads to polyploidy in Rb-downregulated E7 cells.
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CHAPTER II
CBFβ MODULATES CBFβ-SMMHC-ASSOCIATED ACUTE MYELOID
LEUKEMIA IN MICE
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Preface
All of the experiments in this chapter were done by the author with the exception
of the human AML sample analysis, which was done by Peter Valk, Department of
Hematology, Erasmus University Medical Center, Rotterdam, Netherlands.  The work in
this section has been published in:
Heilman SA, Kuo YH, Goudswaard CC, Valk PJM, Castilla LH. The role of Cbfb in
Cbfb/MYH11 associated leukemogenesis. Cancer Research. 2006. 66:11214-8.
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Abstract
The gene encoding the core-binding factor beta (CBFβ) is altered in acute
myeloid leukemia (AML) by an inversion in chromosome 16, resulting in expression of
the fusion protein CBFβ-SMMHC.  Previous studies have determined that this
oncoprotein interferes with hematopoietic differentiation and proliferation, and
participates in leukemia development. In this study, evidence is provided that the
remaining wild-type Cbfβ modulates the oncogenic function of this fusion protein.  Bone
marrow progenitor cells from Cbfb-MYH11 knock-in and Cbfb-knockout mice are used to
study the effect of Cbfβ in hematopoietic differentiation and leukemia progression.  Cbfβ
was determined to play an important role in proliferation of hematopoietic progenitors
expressing Cbfβ-SMMHC in vitro.  In addition, Cbfβ-SMMHC-mediated leukemia
development is accelerated in the absence of a wild-type copy of Cbfβ. These results
provide evidence that the ratio of expression levels between Cbfβ and Cbfβ-SMMHC
directly affects the pathogenesis of leukemia and indicate that CBF-specific therapeutic
molecules should target CBFβ-SMMHC function while maintaining CBFβ activity.
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Introduction
The CBF transcription factor is the most common target of chromosomal
rearrangements in human AML, including the fusion genes CBFB-MYH11 and RUNX1-
ETO (Figure 1.1), as well as point mutations in RUNX1 (Reilly, 2005). CBF is a
heterodimeric transcription factor that consists of a DNA binding α-subunit, encoded by
one of three members of the RUNX family (RUNX1, RUNX2, and RUNX3), and a β-
subunit encoded by the CBFB gene that confers increased DNA-binding affinity to the
complex.  Mouse studies have shown that in hematopoiesis, the CBF heterodimer
Cbfβ:Runx1 regulates expression of genes with critical functions in hematopoietic
differentiation of lymphoid and myeloid lineages. Studies in mouse have determined that
Cbfb-/- and Runx1-/- embryos fail to develop embryonic definitive hematopoiesis and die
at midgestation (Okuda et al, 1996; Sasaki et al, 1996; Wang et al, 1996a; Wang et al,
1996b). This phenotype was rescued in Cbfb-/- mice by expressing Cbfb from the
hematopoietic specific promoters Tie2 or GATA1, further underscoring the key role of
Cbfβ during hematopoietic differentiation (Miller et al, 2002; Yoshida et al, 2002).
Approximately 12% of AML patients present a chromosome 16 inversion,
inv(16), that breaks and joins the first 5 exons of CBFB with the second half of the
smooth muscle myosin heavy chain gene MYH11 (Look, 1997). The resulting fusion
gene, CBFB-MYH11, encodes the CBFβ-SMMHC fusion protein, which retains the
Runx-binding domain from Cbfβ and the multimerization capacity of the myosin
sequence. Studies in the mouse have shown that Cbfβ-SMMHC is a dominant inhibitor of
CBF function, as Cbfb+/MYH11 heterozygous knock-in embryos expressing the fusion
protein also failed to develop definitive hematopoiesis (Castilla et al, 1996).  Induction of
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Cbfβ-SMMHC expression or Runx1-loss in adult bone marrow (BM) does not seem to
affect the maintenance of long-term hematopoietic stem cells (HSC) (Growney et al,
2005; Ichikawa et al, 2004; Kuo et al, 2006). However, Cbfβ-SMMHC expression, acting
as a Class II mutation, reduces HSC function by inhibiting multilineage repopulation and
by creating a myeloid progenitor predisposed to leukemia development.
It has been suggested that Cbfβ-SMMHC may exert an incomplete block of CBF
function.  In this study, the hypothesis that Cbfβ is able to modulate the effect of Cbfβ-
SMMHC in adult hematopoiesis and leukemogenesis is tested.  Mice with a Cbfb knock-
out allele and a conditional Cbfb-MYH11 knock-in allele were used to study adult
myeloid differentiation and leukemia progression. Colony-forming assays revealed that
Cbfβ plays a critical role in proliferation of myeloid progenitors. In addition, loss of Cbfβ
in bone marrow cells expressing Cbfβ-SMMHC induces AML development in the mouse
with faster onset than controls.  These results provide evidence that Cbfβ modulates
hematopoietic differentiation and Cbfβ-SMMHC-mediated leukemia development.
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Materials and Methods
Generation of triple Mx1Cre;Cbfb-/MYH11 transgenic mice.  The design of the
conditional Cbfb+/MYH11 knock-in mice has been previously described (Kuo et al, 2006).
Expression of CBFβ-SMMHC was induced in 3-weeks old mice by activation of Cre
recombinase from the Mx1Cre transgene using 1 to 3 doses of polyinosinic-polycytidylic
acid (pIpC) every other day (Kuhn et al, 1995). Heterozygous Cbfb-/+ knock-out mice
were generously provided by Nancy Speck (Wang et al, 1996b). For this study, all mice
were maintained in the 129SvEv strain. In the transplantation assays, 1x106 leukemic
cells were transplanted into sublethally irradiated syngenic recipients as described
previously (Landrette et al, 2005).
Mice were genotyped with DNA from tail snips obtained at weaning (3 weeks of
age).  Genotyping was done by PCR with the following primers:
Cre  CreA forward CCGGGCTGCCACGACCAA
CreA reverse GGCGCGGCAACACCATTTTT
Cbfb knock-in allele  Hyg forward CCATCGTCGAGATCCAGACATG
Hyg reverse GTATATGCTCCGCATTGGTCTTG
Cbfb null allele  pgk5’ forward CTGACTGCGTTAGCAATTTAAC
Cbfb3' reverse GAAGACCAATAAATGAGAATAAATGC
wild-type Cbfb  I-4 forward ATAAGCAGCAAATAGGTAGAGTG
I-54 reverse CCAGCAGCTGTGAAACTC
Cells isolated from peripheral blood, bone marrow, or methylcellulose colonies
were harvested.  The red blood cells in the peripheral blood and bone marrow were lysed
with Puregene Red Blood Cell (RBC) lysis solution (Gentra Systems).  The remaining
white blood cells were then incubated in proteinase K for 1 hour at 55°C.  PCR for the
deletion was done with the following primers (Figure 2.1):
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4Lx1 forward CAGTGCTCTTGCTAGTGGATC
kT3.1 reverse for the deletion GCTCAACAGTATCAAGAGTCG
h5/6 reverse for the undeleted CTTCTTGCCTCCATTTCCTCC
Immunoblotting.  Western blot was performed as previously described (Kuo et al,
2006). Briefly, total protein extracts were separated by SDS-PAGE and transferred to a
PVDF membrane.  Membranes were blotted with antibodies against Cbfβ (β-141, kindly
provided by Nancy Speck, Dartmouth Medical School) and α-tubulin (Sigma, St. Louis,
MO).
Histopathology.  Peripheral blood was obtained from the retroorbital sinus of the mouse.
White blood cell counts were determined with a hemocytometer after lysing the red blood
cells with RBC lysis solution, washing with PBS, and staining with Trypan Blue (Gibco-
Invitrogen) in a 1:1 volume.  Cellular morphologies were identified after staining
peripheral blood smears with Wright-Giemsa stain.  Histology analysis was performed on
sections from paraffin embedded blocks and stained with Hematoxilin and Eosin
(Histoserv, Gathesburg MD).  Pictures were taken using a Zeiss Axioskop 40 microscope
using 10x, 40x, and 100x lenses and a Zeiss AxioCam Mrc camera.
Flow cytometry Analysis.  Cell-surface antigens were detected by standard immuno-
fluorescence assays using phycoerythrin (PE)-conjugated monoclonal antibodies to Mac1
(1:800), Gr1 (1:800), CD3 (1:400), B220 (1:800), and Sca1 (1:400), Fluorescein (FITC)-
conjugated monoclonal antibodies to Mac1, Gr1, CD3, and B220, Allophycocyanin
(APC)-conjugated monoclonal antibody to c-kit/CD117 (1:1600), PE-Cy7-conjugated
50
monoclonal antibody to FcγR (1:50), and APC-Cy7-conjugated monoclonal antibody to
c-kit (1:100).  PerCP-Cy5.5-conjugated streptavidin (1:200) was used to detect the
biotinylated antibody to CD34 (1:50).  Appropriate isotype controls were included in all
experiments.  All antibodies were obtained from Becton-Dickinson Biosciences (San
Jose, CA) except for APC-Cy7 and Pe-Cy7, which came from eBiosciences (San Diego,
CA).  Fluorescence was analyzed on an LSRII and data was analyzed using FloJo 6.1.1.
Colony forming assays.  Mice with genotypes Cbfb+/56M, Cbfb+/MYH11, Cbfb-/56M, and
Cbfb-/MYH11 were injected with pIpC at weaning,  every other  day.  Two days after the
second injection, BM cells were harvested, and 1x104 white blood cells were plated in
duplicate in methylcellulose supplemented with cytokines IL-3, IL-6 and SCF and
erythropoietin (Methocult-3434, Stem Cell Technologies, Vancouver) in 35 mm non-
tissue culture treated dishes.  The number of erythroid and total colonies was scored at
day 4.  The number of myeloid colonies was scored at day 7. Single colonies were
harvested and either cytospun for cytology analysis or placed into lysis buffer for PCR
analysis. Pictures were taken with a Zeiss AxioCam Mrc camera.
Statistical considerations.  Differences in survival functions between groups were
evaluated by Kaplan-Meier product limit survival analysis using the Tarone-Ware test to
test the hypothesis of overall equivalence.  In the presence of significant overall
differences pair-wise comparisons were made between the non-control groups using
Tarone-Ware tests with a Sidak adjustment to compensate for the additive Type I error
due to multiple comparisons.
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Analysis of human AML samples.  Patients had a diagnosis of primary AML,
confirmed by cytological examination of blood and bone marrow. After informed
consent, bone marrow aspirates or peripheral blood samples were taken at diagnosis
(n=285) and processed for the Affymetrix U133A GeneChip analysis (Valk et al, 2004).
For PCR and sequence analyses, cDNA prepared from 50ng of RNA was used for all
PCR amplifications. The CBFB coding region was sequenced for 27 inv(16)+ AML
samples by cDNA amplification using the primers:
CBFB-FOR 5'-CAGAGAAGCAAGTTCGAGAACG-3' with
CBFB-REV 5'-GTTTGAGGTCATCACCACCAC-3'
CBFB-FOR with CBFB6 5’-GTCTTGTTGTCTTCTTGCCAG-3’
with the recipe 25mM dNTP, 15 pmol primers, 2mM MgCl2, Taq polymerase and
10xbuffer (Invitrogen Life Technologies, Breda, Netherlands). Cycling conditions for
both primer sets consisted of a denaturing cycle for 5 min at 94˚C followed by 30 cycles
for amplification (1 min 94˚C, 1 min 62˚C, 1 min 72˚C), and a final extension cycle for 7
min at 72˚C. PCR products were purified using the Multiscreen-PCR 96-well system
(Millipore, Bedford, MA) followed by direct sequencing with CBFB-FOR, CBFB-REV
and CBFB6 using an ABI-PRISM3100 genetic analyzer (Applied Biosytems, Foster City,
CA).
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Results
Loss of Cbfβ reduces proliferation capacity of myeloid progenitors expressing Cbfβ-
SMMHC in vitro.  It has recently been shown that BM cells expressing Cbfβ-SMMHC
accumulate abnormal myeloid progenitors able to form myeloid colonies in vitro (Kuo et
al, 2006). To assess whether this effect is dependent on the presence of Cbfβ,  colony-
forming unit (CFU) assays were performed using BM cells from heterozygous floxed
(Cbfb+/56M), hemizygous floxed (Cbfb-/56M), heterozygous restored (Cbfb+/MYH11), and
hemizygous restored (Cbfb-/MYH11) mice (Figure 2.1). The expression of the fusion protein
Cbfβ-SMMHC, which switches the floxed to the restored allele, was induced by pIpC
treatment-mediated Cre activation using the Mx1Cre transgene.  Excision of the knocked-
in sequence was confirmed by PCR analysis.
The number of colony forming units (CFUs) at day 7 was significantly reduced in
hemizygous restored BM progenitor cells expressing Cbfβ-SMMHC when compared to
control groups (Figure 2.2A). In addition, the loss of one Cbfb allele did not affect CFU
formation (heterozygous floxed vs. hemizygous floxed), indicating that the observed
phenotype results from a reduction below 50% of the Cbfb transcript. The presence of
Cre-lox mediated deletion was confirmed in CFUs from hemizygous restored plates by
PCR analysis (Figure 2.2B). The same increases and decreases in colony number were
seen for the blast forming erythroid unit (BFU-E) colonies counted on day 4 as well
(Figure 2.2A). Interestingly, the size of the colonies was markedly reduced in
hemizygous restored plates when compared to control plates (Figure 2.2C).
Cytology analysis of day-7 CFUs revealed the presence of all myeloid forms, with
a small but consistent increase of blastlike immature cells in hemizygous restored
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Figure 2.1. Cbfb alleles used in this study. Exons 1 to 6 of the Cbfb gene are shown in
boxes, and the encoded protein is shown on the right. The Cbfb knock-out allele includes
a Neomycin (N) gene fused to the 3’-end of exon 5. The floxed Cbfb56M allele includes
exons 5 and 6 and a Hygromycin gene (H) between loxP sites, followed by exon 5 fused
to the 3’ MYH11 sequence and a Neomycin gene. Upon Cre-mediated loxP deletion,
Cbfβ-SMMHC is induced in the CbfbMYH11 restored allele.  PCR analysis for loxP
deletion was done using primers 4Lx1, KT3, and h5/6.
No protein
Cbfb
Cbfb-SMMHC
Cbfb
Cbfb Alleles Encoded proteins
Cbfb56M
floxed
Cbfb-
CbfbMYH11
restored
54321 MYH N
54321 MYH N
54321 N
54321Cbfb
+
Cre
5 6 H 6
6
6
6
H5/6
KT3
4xL
250bp
150bp4xL
Figure 2.1
54
55
Figure 2.2. Cbfβ modulates BM myeloid proliferation in vitro. Colony forming assays
in methylcellulose cultures using 1x104 BM hematopoietic progenitor cells with
heterozygous floxed (Cbfb+/56M), heterozygous restored (Cbfb+/MYH11), hemizygous
floxed (Cbfb-/56M) or hemizygous restored (Cbfb-/MYH11) genotypes.  A. Scored at days 4
and 7.  Data is from three independent experiments, each in duplicate. B: PCR for the
deletion of the conditional knock-in exons 5 and 6.  C. Representative picture of colony
size (amplification 50x) from day 7. D. Histogram representation of cytology analysis of
day 7 GEMM-, Blast-, GM-, M-, and G-CFUs.  Data is from three independent
experiments, each in duplicate.
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colonies (Figure 2.2D). However, the Cbfb+/MYH11 cells formed more CFU-G
(granulocyte) and CFU-GM (granulocyte/macrophage) colonies, and the Cbfb-/MYH11 cells
appeared to have an impairment in granulocyte formation (decrease in CFU-G) and had
an increase in macrophage/monocyte (CFU-M) formation. The BFU-E colonies seen in
all genotypes at day 4 and the variety of myeloid colonies (CFU-GM, CFU-GEMM
(granulocyte, erythroid, macrophage, monocyte)) seen at day 7 distinguish these cells as
having maintained both erythroid and myeloid differentiation potential in all of these
genotypes.  These results revealed that the loss of Cbfβ significantly reduces the
proliferation capacity of BM myeloid progenitors expressing CBFβ-SMMHC in vitro.
These results are in accordance with studies using Cbfb-/- embryonic stem cells, in which
loss of Cbfβ was shown to inhibit formation of myeloid colonies (Miller et al, 2001).
Furthermore, while ectopic Cbfβ expression restored colony formation in Cbfb-/-
embryonic stem cells, CBFβ-SMMHC was intrinsically unable to restore CBF function
(Miller et al, 2001).
Hemizygous BM cells expressing Cbfβ-SMMHC show higher susceptibility to AML.
The Cbfb+/MYH11 mice expressing Cbfβ-SMMHC and Cbfβ succumb to AML with a
median latency of 5 months due to acquisition of random cooperating Class I mutations
(Kuo et al, 2006). This latency is dose-dependent as mice treated with 3 pIpC doses
developed AML with a median latency of 5 months, mice treated with 1 pIpC dose with a
median latency of 8 months, and untreated mice remained disease free up to one year
(end of experiment).
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To test whether the presence of Cbfβ has an effect on Cbfβ-SMMHC-mediated
AML, we compared heterozygous restored to hemizygous restored mice, after treatment
with 3 doses of pIpC.  In the absence of Cbfβ, 100% of mice with BM cells expressing
Cbfβ-SMMHC developed AML with a significant acceleration of disease onset (median
latency of 1.5 ± 0.5 months; p<1e-5; Figure 2.3A). Surprisingly, untreated Cbfb-/MYH11 -
mice also developed AML with a similar latency to that of the induced group (Figure
2.3A). It has previously been reported that Cre expression from the Mx1Cre transgene is
leaky in mice not treated with pIpC (Chan et al, 2004). In this study, all AML samples
from treated and untreated groups exhibited deletion of the floxed sequence by PCR
analysis (Figure 2.3B), and Cbfβ-SMMHC expression was detected by western blot
analysis (Figure 2.3C). Furthermore, secondary transplantation of Cbfb-/MYH11 AML cells
derived from treated or untreated mice produced leukemia in sublethally irradiated
recipients with a median latency of 6 weeks (data not shown). These results indicate that
Cbfβ-SMMHC-induced AML development is accelerated in the absence of Cbfβ.
 Expression of Cbfβ is critical for the emergence of embryonic HSCs (Miller et al,
2002). However, while 50% reduction of Cbfβ levels does not seem to alter
hematopoiesis, the effect of Cbfβ levels below 50% in adult BM progenitors has not been
previously tested. Based on our results, however, we cannot definitively rule-out that
Cbfβ-loss could induce AML in the absence of Cbfβ-SMMHC. Future studies using
conditional Cbfb knock-out mice or Cbfβ-shRNA approaches may directly address this
point. However, considering that loss of Runx1 in HSCs using conditional knock-out
mice does not induce AML (Growney et al, 2005; Ichikawa et al, 2004), the disease
phenotype observed in our study is likely dependent on the presence of Cbfβ-SMMHC.
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Figure 2.3. Loss of wild-type Cbfb accelerates Cbfb-SMMHC-mediated AML.  A.
Kaplan-Meier survival curve of mice expressing Cbfβ-SMMHC in the presence or
absence of Cbfβ.  Cbfb+/56M mice (open circles), Cbfb-/56M mice (tics), Cbfb+/MYH11 mice
with 3 shots of pIpC (triangles), Cbfb-/MYH11 mice with 3 shots of pIpC (squares), Cbfb-
/MYH11 mice with 1 shot of pIpC (crosses), and Cbfb-/MYH11 mice with no pIpC (closed
circles). B. PCR analysis of peripheral blood and bone marrow samples for the deletion
of the conditional knock-in of exons 5 and 6 in Cbfb-/MYH11 mice that developed leukemia
without induction with pIpC. C. Western blot analyses of Cbfβ-SMMHC and β-actin in
AML samples derived from restored Cbfb mice treated (or untreated) with pIpC. The
Cbfb genotype of the AML cells is shown on the top.
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Importantly, our findings that uninduced Cbfb-/MYH11 mice succumb with AML at short
latency and that secondary AML develops in sublethally irradiated recipients, strongly
support the model that the disease results from the clonal expansion of a few abnormal
BM hematopoietic progenitors within a normal hematopoietic environment.
Disease pathology is dictated by Cbfβ-SMMHC.  The hemizygous leukemic Cbfb-
/MYH11 mice presented an increase in white blood cell count (mean = 41.7 ± 74.7 x106/mL)
when compared to healthy littermates (mean = 4 x106/mL), although lower than that
observed in heterozygous leukemic Cbfb+/MYH11 mice (mean = 197.5 ± 170.3 x106/mL).
As previously seen in heterozygous restored leukemic mice, the leukemic cells from the
hemizygous mice also included predominantly blastlike and myelo-monocytic cells
(Figure 2.4, top row) with the characteristic cell-surface profile c-kit+/ Lin- (Figure 2.5A).
The peripheral blood smears, stained with Wright Giemsa, also showed severe anemia
characterized by a significant decrease in the number of red blood cells (Figure 2.4,
second row)
The bone marrow of the leukemic mice was also similarly affected between the
heterozygous and hemizygous restored mice.  Histology analysis shows an infiltration of
immature cells into the bone marrow, causing a decrease in the number of fat cells and
the number of red blood cells and capillaries running through the bone marrow (Figure
2.4, third row).  The heterozygous restored leukemic mice had a decrease in the number
of megakaryocytes seen in the bone marrow, and those that were present were immature
(Kuo et al, 2006).  The hemizygous restored leukemic mice had no observable
megakaryocytes in the bone marrow, which again suggests that the fusion protein has an
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Figure 2.4. Pathology of disease in Cbfb+/MYH11 and Cbfb-/MYH11 leukemic mice.  Top
row- Peripheral blood smears stained with Wright-Giemsa (1000X mag) Second row-
Peripheral blood smears stained with Wright-Giemsa (400X). Third row- Bone marrow
sections from tibia stained with H&E (400X) Fourth row- Disruption of spleenic
architecture (400X) Spleen sections stained with H&E. Bottom row- The presence of
infiltrating leukemia cells in the liver (400x) Liver sections stained with H&E.  Cells
analyzed from wild type control (left column), and leukemic mice expressing Cbfβ-
SMMHC in the presence (middle column) or absence (right column) of Cbfβ.
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incomplete block of CBF function and that the combined lack of Cbfβ makes this
blockage complete.
Leukemic mice with the presence of the fusion also presented with severe
splenomegaly.  Although the average spleen weight for the hemizygous restored mice
(0.85 ± 0.52 g) was lower than for the heterozygous restored mice (2.01 ± 0.76 g), it is
still significantly greater than the average spleen weight of a healthy mouse (0.06 ± 0.01
g).  The lower spleen weight is most likely due to the shorter latency period, which does
not allow as much time for the spleen to become infiltrated and enlarged.  Histology
analysis of the spleen confirms the disruption of normal splenic architecture.  The
displacement of the normal population of B-cells and T-cells by the infiltrating immature
cells causes a lack of organized white pulp and a decrease in the amount of red pulp.
(Figure 2.4, fourth row).
Histological analysis of the liver showed an infiltration of leukemic cells into the
interstitial spaces and between the hepatocytes focused near the capillaries (Figure 2.4,
bottom row). Compromise of the thymus and lymph nodes was not observed, which
supports the conclusion that this is a myeloid and not a lymphoid disease.  Taken
together, the pathology of disease in hemizygous and heterozygous mice was similar,
suggesting that the AML phenotype was determined by the presence of Cbfβ-SMMHC.
Peripheral blood from Cbfb+/MYH11 and Cbfb-/MYH11 leukemic mice shows a decrease
in differentiated cells and an increase in progenitor cells.  To further characterize the
leukemic cells, flow cytometry was performed on the peripheral blood from the leukemic
mice at the time of sacrifice (See Materials and Methods).  Heterozygous and
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hemizygous restored leukemic mice both had a decrease in the percentage of
differentiated cells- Gr1+ (granulocytes), Mac1+ (macrophages), CD3+ (T-cells), and
B220+ (B-cells) and an increase in the percentage of c-kit+ cells in the peripheral blood
(Figure 2.5A).  This represents an overall increase in progenitor cells and a decrease in
the percentage of differentiated myeloid and lymphoid cells, which suggests a block in
differentiation.
Bone marrow from Cbfb+/MYH11 and Cbfb-/MYH11 pre-leukemic mice shows an
increase in myeloid progenitor cells.  To further examine the in vivo effect of the lack
of Cbfβ in mice with the fusion protein, a pre-leukemic analysis was done on the bone
marrow of these mice.  The myeloid progenitor compartment was analyzed by flow
cytometry using the progenitor markers Sca1 and c-kit (Akashi et al, 2000).  In both the
heterozygous and hemizygous pre-leukemic mice there was a small increase in the HSC
population (Lin-/Sca1+/c-kit+) and a dramatic (~20 fold) increase in the myeloid
progenitor population (Lin-/Sca1-/ckit+) (Figure 2.5B).  This effect was similar to that
seen by Kundu et al (2003) in CbfbGFP/GFP embryos and by Miller et al (2002) in Cbfb-/-
;Tek-Cbfb rescued embryos (Kundu & Liu, 2003; Miller et al, 2002).  The myeloid
progenitor population was then sorted with the early progenitor markers FcγR and CD34
(Akashi et al, 2000).  The granulocyte/macrophage progenitor (GMP: FcγR+/CD34+) and
common myeloid progenitor (CMP: FcγR-/CD34+) populations changed very little
compared to the wild-type control mice.  However the megakaryocyte/erythroid
progenitor (MEP: FcγR-/CD34-) population had a very significant increase in both of the
pre-leukemic genotypes (Figure 2.5B).  These progenitor cells from the Cbfb+/MYH11 mice
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Figure 2.5. Flow cytometry analysis of Cbfb+/MYH11 and Cbfb-/MYH11 leukemic and
pre-leukemic mice.  A: Flow cytometry analysis of peripheral blood from wild-type and
leukemic Cbfb+/MYH11 and Cbfb-/MYH11 mice using lineage markers Mac1 (macrophages),
Gr1 (granulocytes), CD3 (T-cells), and B220 (B-cells) and the progenitor marker c-kit.
B: Flow cytometry analysis of bone marrow from wild-type and pre-leukemic
Cbfb+/MYH11 and Cbfb-/MYH11 mice looking at Lin- cells using progenitor markers Sca1 and
c-kit to examine hematopoietic stem cells and myeloid progenitor cells, and early
progenitor markers FcγR and CD34 to examine MEPs, CMPs, and GMPs.
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are the abnormal myeloid progenitors (AMPs) seen in Kuo et al (2006) (Kuo et al, 2006),
which suggests that the progenitor cells from the Cbfb-/MYH11 mice are also AMPs.
The wild type CBFB allele is not a frequent target of mutations in inv(16) AML. The
results obtained in the mouse prompted us to investigate whether CBFB was altered in
human CBFB/MYH11 AML samples. First, sequence analysis of the CBFB coding region
in a panel of 29 inv(16) AML samples identified no mutations, in concordance with a
previous report in 2 inv(16) AML samples (Leroy et al, 2002). In addition, analysis of
CBFB transcript levels in a panel of 285 human AML samples indicated that inv(16)
AML samples had a reduction of 40% of the CBFB transcript when compared to CD34+
BM cells (relative value: 0.4±0.08), as expected by the expression of one CBFB allele.
The CBFB levels in t(8;21) and non-CBF cytogenetic groups were unchanged (t(8;21)
relative value = 0.9±2.3; non-CBF relative value = 1.0±0.32). These results indicate that a
wild type CBFB transcript may be expressed at reduced levels in inv(16) AML cells as a
consequence of the inv(16), but additional genetic alterations are not common in the
CBFB locus. The possible role of CBFβ as a tumor suppressor in human leukemia by
post-transcriptional regulation mechanisms, however, cannot be ruled-out.
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Discussion
Endogenous expression of Cbfβ-SMMHC from the Cbfb allele in conditional
knock-in mice is a “class II” mutation, which creates an AMP cell that is able to progress
to AML in a multistep process (Kuo et al, 2006). Although the fusion protein is thought
to act as a dominant factor in differentiation and transformation (Castilla et al, 1999;
Castilla et al, 1996; Kuo et al, 2006), the role of wild-type Cbfβ in Cbfβ-SMMHC
mediated leukemia is not clear. Here we showed that the capacity of Cbfβ-SMMHC to
induce AML in mice is modulated by wild-type Cbfβ in vivo.
Previous studies have shown that Cbfβ is critical for embryonic definitive
hematopoiesis (Wang et al, 1996b), and for in vitro myeloid differentiation from Cbfb-/-
embryonic stem cells (Miller et al, 2001).  This study indicates that Cbfβ is necessary for
in vitro myeloid-erythroid differentiation of BM-hematopoietic progenitors. In addition,
since colonies were drastically reduced in the absence of Cbfβ, but not in the presence of
Cbfβ-SMMHC, these results support the hypothesis that Cbfβ-SMMHC may have an
incomplete effect in differentiation. As Cbfβ and Cbfβ-SMMHC compete for binding
with Runx proteins in BM cells, basal levels of the Cbfβ:Runx1 complex in
hematopoietic progenitors expressing Cbfβ-SMMHC may be critical for proliferation of
myeloid progenitors and result in a delay in transformation.
In vitro data does not show Cbfb-/MYH11 cells with an increased ability to
proliferate.  Instead, the increase in progenitor cells provides a larger more susceptible
pool of cells that are prone to acquiring proliferative mutations.  The full block in
differentiation may cause acceleration of this natural acquisition of genetic aberrations.
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Endogenous expression of Cbfβ-SMMHC and Cbfβ in BM induces AML with a
median latency of 5 months (Kuo et al, 2006).  Upon the Cre-lox-mediated switch from
Cbfβ to Cbfβ-SMMHC expression in progenitor cells lacking a wild type Cbfb allele,
AML latency was shortened to 6 weeks. This finding strongly suggests that Cbfβ-
SMMHC function is enhanced by wild-type Cbfβ loss.
The Cbfb-/MYH11 mice studied here present with all the characteristics of leukemia.
White blood cell counts are significantly increased and peripheral blood smears show
severe anemia.  Flow cytometry analysis of the peripheral blood shows a block in the
differentiation of hematopoietic cells including granulocytes, macrophages, T-cells, and
B-cells.  There is also an increase in the number of myeloid progenitor cells, which look
immuno-histochemically like MEPs but morphologically may represent CMPs, MEPs, or
GMPs.  Histological analysis of hematopoietic tissues shows infiltration of immature
leukemic cells in the bone marrow, spleen, and liver, but not the thymus or lymph nodes.
Lastly, bone marrow and spleen cells from Cbfb-/MYH11 leukemic mice are transplantable
into wild-type recipient mice with latency similar to that of Cbfb+/MYH11 leukemic mice.
In Cbfb-/MYH11 leukemic mice there is a smaller increase in the number of white
blood cells in the peripheral blood, compared to the leukemic Cbfb+/MYYH11 mice.  In
Cbfb+/MYYH11 mice, it is probable that the wild-type copy of Cbfb provides a partial rescue
of the differentiation block.  In Cbfb-/MYYH11 mice, a wild-type copy of Cbfb is not present
to rescue the block in differentiation in the hematopoietic cells; therefore there is more of
a complete block in differentiation.  As in the less severe splenomegaly, time may also be
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a factor in accumulation of white blood cells.  Because of the shorter latency, there is not
as much time to amass more white blood cells.
Normally, the number of colonies at day 7 reflects the number of progenitor cells
plated.  Because Cbfβ-SMMHC causes a block in differentiation, an increase in the
number of progenitor cells and therefore the number of colonies from Cbfβ-SMMHC
expressing cells would be expected. This is the case for the Cbfb+/MYH11 pre-leukemic
bone marrow, however there is a decrease in the number of colonies from the Cbfb-/MYH11
pre-leukemic bone marrow.  In the Cbfb-/MYH11 expressing cells, there are two possible
explanations for decrease in colony number.  First, is possible that there is actually a
decrease in the number of progenitor cells with this genotype.  This is unlikely, since the
presence of the fusion protein alone causes an increase in the number of progenitors due
to a block in differentiation and the lack of Cbfb does not reverse that effect.  The other
possibility is that there are progenitor cells present, but that they are unable to proliferate
adequately to create a large enough colony to count.  The relatively small and less dense
colonies seen in the Cbfb-/MYH11 cells support this latter hypothesis.  In vitro over-
expression experiments also show that CBFβ-SMMHC slows cell proliferation at the G1
to S cell cycle transition (Cao et al, 1998; Cao et al, 1997).
Cytological analysis of the pre-leukemic bone marrow showed the expected
increase in blast colonies in those colonies containing Cbfβ-SMMHC, although in the
absence of Cbfβ there is a slightly greater increase in the percentage of blast colonies.
This suggests a greater block in differentiation in the Cbfb-/MYH11 mice.  Those colonies
expressing Cbfβ-SMMHC and lacking wild-type Cbfβ showed significant decreases in
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the percentage of CFU-G and CFU-GM colonies compared to controls.  Those colonies
with both the fusion protein and wild-type Cbfβ showed significant increases in CFU-G
and decreases in CFU-M.  This suggests that the differentiation block may be slightly
different between these two genotypes, and that the presence of the fusion protein in pre-
leukemic bone marrow cells causes a block in differentiation at the CMP level, an
increase in progenitor cells, and no significant change in proliferation.
Surprisingly, a similar AML latency was observed between induced and
uninduced groups.  Probably, a small progenitor population underwent Cre/lox deletion
due to ‘‘leaky’’ Cre expression from the Mx1Cre transgene (Chan et al, 2004), and thus
expressed the Cbfb/MYH11 fusion gene. Importantly, all AML samples presented the Cre
mediated deletion, suggesting that transformation is due to the Cbfβ to Cbfβ-SMMHC
switch. Furthermore, the finding that CBFB is not frequently lost in human AML argues
against its role as an inv(16) cooperating tumor suppressor in AML. Rather, our results
suggest that an increase in the Cbfβ-SMMHC to Cbfβ ratio reduced proliferation of
myeloid progenitors while increasing their susceptibility to neoplastic transformation,
although the underlying mechanism is unclear.  However, this study cannot rule out the
possibility that Cbfb loss in bone marrow could induce AML. The generation of
conditional Cbfb knockout alleles will provide a critical tool to directly address this
possibility using a genetic approach.
Runx2 has previously been shown to cooperate with Cbfb/MYH11 to cause
leukemia (Castilla et al, 2004).  This result presents a novel idea, because both mutations,
a block in differentiation and an increase in proliferation, occur in the same pathway.
Together, these results highlight the importance of the CBF transcription factor in
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regulation of hematopoiesis and contribution to leukemogenesis.  Finally, these findings
have important implications on the design of targeted therapies. One possibility is the
identification of drugs that inhibit the fusion protein. Whereas candidate molecules
should act to disrupt Cbfβ-SMMHC:Runx1 binding, it will be critical that CBFβ:Runx1
binding remains unaltered.
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CHAPTER III
ABROGATION OF THE POSTMITOTIC CHECKPOINT CONTRIBUTES TO
POLYPLOIDIZATION IN E7 EXPRESSING, RB-DOWNREGULATED CELLS
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Preface
All of the experiments in this chapter were done by the author with the exception
of the time-lapse videomicroscopy, which was done by Joshua Nordberg, in the
laboratory of Greenfield Sluder, Department of Cell Biology, University of
Massachusetts Medical School and analyzed by the author.  The work in this section has
been submitted for publication:
Heilman SA, Nordberg JJ, Liu YW, Sluder G, Chen JJ. HPV-E7 induces polyploidy
through abrogation of a novel post-mitotic checkpoint.
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Abstract
Polyploidy predisposes human cells to aneuploidy, an early event in multistep
carcinogenesis.  Cells with defective retinoblastoma (Rb) protein, which is functionally
inactivated in the majority of human cancers, have a high incidence of polyploidy.
However, the mechanism of polyploidization in Rb-downregulated cells is not known,
and current hypotheses are conflicting.  Previous proposed mechanisms include spindle
assembly checkpoint abrogation, DNA re-replication without an intervening mitosis,
cleavage failure, and/or a relaxed postmitotic checkpoint.  This study explores these
possibilities to better characterize the mechanism by which Rb-downregulation leads to
polyploidization.  We find that Rb-defective mouse and human cells undergo normal
mitoses with an intact spindle assembly checkpoint and complete cytokinesis. Our results
also exclude DNA re-replication as a major mechanism of polyploidization in Rb-
downregulated cells upon microtubule disruption. While normal cells arrest in G1 with
4C DNA content after adaptation to the spindle assembly checkpoint, Rb-downregulated
cells replicate their DNA after mitosis and propagate as polyploid cells. Thus, our data
indicate that Rb-downregulation leads to abrogation of the postmitotic checkpoint, which
allows polyploidization.
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Introduction
An important hallmark of human cancers is aneuploidy, the state in which a cell
has extra or missing chromosomes (Nasmyth, 2002; Pellman, 2007).  Polyploidy, the
state in which cells have more than two sets of chromosomes, is thought to be an early
event in multi-step carcinogenesis that can lead to aneuploidy (Andreassen et al, 2001;
Meraldi et al, 2002), as exemplified in Barrett’s esophagus (Galipeau et al, 1996).
Polyploidy has recently been shown to not only occur as an early event in cervical
carcinogenesis, but to predispose the cells to aneuploidy (Olaharski et al, 2006).  Other
recent studies have shown that tetraploid, but not diploid, mouse or human cells induce
tumor formation in mice (Duelli et al, 2007; Fujiwara et al, 2005).  These studies
highlight the potential importance of polyploidy in carcinogenesis.
The retinoblastoma (Rb) tumor suppressor protein is functionally inactivated in
the majority of human cancers (Hanahan & Weinberg, 2000).  Rb blocks proliferation of
cells by sequestering members of the E2F family of transcription factors, which are
essential for G1 to S-phase progression (Weinberg, 1995).  Downregulation of Rb has
been shown to spontaneously induce polyploidy in cycling cells (Hernando et al, 2004;
Iovino et al, 2006) or in cells under mitotic stress caused by nocodazole or colcemid (Di
Leonardo et al, 1997; Khan & Wahl, 1998; Lentini et al, 2002), suggesting that pRb may
be a major regulator of the mechanism that controls cellular ploidy (Lentini et al, 2002).
The cellular mechanisms responsible for this polyploidization are as yet
undetermined, but several models have been proposed.  When cells with an intact spindle
assembly checkpoint become arrested during mitosis for a prolonged period of time, they
eventually adapt to the checkpoint, exit mitosis without cleavage, and progress into a G1-
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like state with 4C DNA content (Lanni & Jacks, 1998; Margolis et al, 2003). The cells
are prevented from continuing through the cell cycle and replicating their DNA by a
proposed p53- and pRb-dependent postmitotic checkpoint (Khan & Wahl, 1998; Lanni &
Jacks, 1998).  The first model proposes that abrogation of this checkpoint allows the cells
to replicate their 4C DNA leading to proliferation of the polyploid cells.  This has been
shown in cells that express the HPV-16 E6 oncogene that degrades p53 (Liu et al).
A second proposed model for polyploidization in Rb-downregulated cells is re-
replication, a process of multiple rounds of DNA replication without an intervening
mitosis.  It was previously proposed that Rb is involved in preventing DNA re-replication
and that downregulation of Rb may allow cells to  become polyploid (Lentini et al, 2002).
Another proposal is abrogation of the spindle assembly checkpoint followed by cleavage
failure, which may lead to polyploidization (Taylor & McKeon, 1997; Vogel et al, 2004)
in Rb-downregulated cells (Thomas & Laimins, 1998).  Hernando et al (2004) suggested
that Rb-downregulation affects the spindle checkpoint through upregulation of Mad2 due
to deregulation of E2F activity (Hernando et al, 2004). Finally, cleavage failure, which
yields binucleate cells with 4C DNA content, is also a potential mechanism to
polyploidization (Shi & King, 2005).  In this study, I investigate these possibilities to
determine the mechanism that leads to polyploidization in Rb-downregulated cells.
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Materials and Methods
Cell Culture. Mouse embryonic fibroblasts (MEFs) (provided by Stephen Jones,
Department of Cell Biology, University of Massachusetts Medical School) were
maintained in Dulbecco’s modified Eagle medium (DMEM) plus 15% fetal bovine serum
(FBS).  Primary human keratinocytes (PHKs) were derived from neonatal human
foreskin epithelium obtained from the University of Massachusetts Hospital as described
(Liu et al). These cells were maintained on mitomycin C-treated J2-3T3 feeder cells in F-
medium composed of 3 parts Ham’s F12 medium and 1 part DMEM plus 5% FBS with
all supplements as previously described (Flores et al, 2000).  The hTERT-expressing
human retinal pigment epithelial cells (RPE1) (Uetake & Sluder, 2004) were maintained
in 1:1 DMEM and Ham’s F12 medium plus 10% FBS.
Retroviral Infections.  PHKs and RPE1 cells expressing vector or E7 were established
by retrovirus-mediated infection using the pBabe-puro-based retroviral construct.  After
puromycin selection (0.75 µg/mL for PHKs and 10 µg/mL for RPE1 cells), populations
of infected cells were pooled.  PHKs were maintained in 0.2 µg/mL puromycin and used
within 5 passages.  RPE1 cells were maintained in 2 µg/mL puromycin and used within 8
passages.  E7 expression was confirmed by RT-PCR using previously described oligos
(Liu et al) and by Western blot.
Immunoblotting. Protein extraction was performed in RIPA lysis buffer (150 mM NaCl,
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, 5mM EDTA, protease
inhibitors (Complete Mini EDTA-free, Roche)).  Protein concentrations were determined
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by bicinchoninic acid (BCA) analysis (Pierce).  Equal amounts of protein from each cell
lysate were separated by SDS-PAGE and transferred onto a PVDF membrane.  The
membranes were blotted with antibodies against E7 (Santa Cruz), pRb (BD Biosciences),
cyclin B1 (BD Biosciences), cyclin D1 (Santa Cruz), cyclin E (BD Biosciences), and β-
tubulin (Sigma). Immunoreactive proteins were visualized with SuperSignal West
Femto Maximum Sensitivity Substrate (Pierce). The membranes were scanned with an
LAS-1000 Image Reader (Fuji Photo Film Inc.).
Flow cytometry. Asynchronous cultures of cells were treated with DMSO (Sigma),
nocodazole (Sigma, 50 ng/mL), or Monastrol (Sigma, 100 µM).  For the polyploidy
experiments, the cells were harvested, fixed in 70% ethanol, and resuspended in a PBS-
propidium iodide (PI, Sigma, 50 µg/mL)-RNase A (Sigma, 70 µg/mL) solution.  For the
mitotic index and mitotic shake-off experiments, the cells were harvested at 12, 16, 20,
24, 28, 40, 42, 48 or 72 hours, fixed in 70% ethanol, permeablized in 0.25% Triton X-
100, stained with 0.5 µg of the rat anti-phospho-histone H3 IgG2a (Sigma) and then with
fluorescein isothiocyanate (FITC)-conjugated anti-rat IgG2a (BD Biosciences), and
counter-stained with PBS-PI-RNase A.  For the BrdU labeling experiments, the plated
cells were incubated with BrdU (final 10 µM) for 2 hours before being harvested and
fixed in 70% ethanol.  After fixation, the cells were permeablized with 2 N HCl/ 0.5%
Triton X-100, neutralized with 0.1 M sodium tetraborate, stained with anti-BrdU-FITC
(BD Biosciences), stained with anti-mouse IgG (Fab)2-FITC (Sigma), and counter-stained
with PBS-PI-RNase A.  Cell cycle analysis was performed using FlowJo software
(Becton Dickinson).
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Time-Lapse Videomicroscopy.  Live-cell imaging was performed as previously
described (Sluder et al, 2004).  Briefly, RPE1 cells or MEFs were grown on glass 22 x 22
mm coverslips in low HEPES (12.5 mM) DMEM for time-lapse videomicroscopy.  Phase
contrast images were acquired on a Leica DMIRE2 inverted microscope with a 10x
objective lens, and images were acquired using Openlab 3.5.2 (Improvision, Inc.,
Lexington, MA) and recorded using a Q-Imaging Retiga Exi camera.  Images were taken
every 3 minutes with a 3 second exposure and later compressed to view as a movie using
Quicktime 6.5 (Apple Computer, Inc., Cupertino, CA).
Statistical Analysis. Data were expressed as mean ± standard deviation. Differences
between means were assessed by Student's t-test. p ≤ 0.05 was considered significant.
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Results
Rb downregulation results in polyploidy.  It has been shown that downregulation of Rb
in mouse and human fibroblasts leads to spontaneous polyploidization (Hernando et al,
2004; Iovino et al, 2006).  We first tested these results in our own cells by comparing
Rb-/- MEFs to wild-type MEFs.  As shown in Figure 3.1, Rb-/- MEFs have 5-fold more
cells with DNA content greater than 4C compared to wild-type controls (14.5% vs.
3.0%).  Previous studies showed that treatment with nocodazole, which disrupts
microtubule stability, enhances polyploidization in Rb-/- MEFs (Di Leonardo et al, 1997;
Khan & Wahl, 1998; Lentini et al, 2002).  Our study also showed that arresting Rb-/-
MEFs in mitosis with nocodazole, where they eventually adapt to the spindle assembly
checkpoint, results in double the amount of polyploidy compared to untreated cells
(28.3% vs. 14.5%, Figure 3.1).  This confirms that lack of Rb in MEFs can lead to
polyploidy in our cells, both spontaneously and in response to microtubule
depolymerizing drugs.
Next we examined the effect of Rb-downregulation in human epithelial cells, the
tissue type from where the majority of human solid tumors arise (Christofori & Semb,
1999).  Since no matched human cell lines defective for Rb are available, we used the
human papillomavirus type 16 (HPV-16) oncogene E7 to downregulate pRb.  HPV-16 E7
is known to bind pRb and promote its degradation (Demers et al, 1994; Dyson et al,
1989).  Stable cell lines were created by infection of both primary human keratinocytes
(PHKs) and hTERT-immortalized human retinal pigment epithelial (RPE1) cells with
retroviruses containing E7 or empty vector.  E7 expression in the stable cell lines was
confirmed by RT-PCR (Figure 3.2A) and by Western blot (Figure 3.2B).  As
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Figure 3.1.  Rb downregulation results in polyploidy formation.  Asynchronous
cultures of wild-type and Rb-/- MEFs were treated with DMSO or nocodazole (50
ng/mL) for 48 hours.
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Figure 3.2.  E7 expression results in polyploidy formation.  A. Total RNA isolated
from PHKs and RPE1 cells expressing vector or E7 were subjected to RT-PCR using
specific primers.  The products were resolved on a 1% agarose gel.  β-actin was used as a
control.  B. Total protein extracts from PHKs and RPE1 cells expressing vector or E7
were resolved by SDS-PAGE and blotted with antibodies against E7, pRb, and tubulin.
C. Untreated RPE1 cells expressing E7 or vector were harvested, fixed, and stained with
PI.  The percentages of polyploidy (>4C DNA content) was measured and averaged.  (*
p<0.001) D. Asynchronous cultures of RPE1 cells and PHKs expressing vector or E7
were treated with DMSO, nocodazole (50 ng/mL), or Monastrol (100 µM). Seventy-two
or forty-eight hours later, the RPE1 cells and PHKs, respectively, were collected, fixed,
stained with PI, and analyzed by flow cytometry.  Data from a representative experiment
(of 3) are shown.  The percentages of cells with more than 4C DNA content are indicated.
E. Cells under nocodazole treatment (50 ng/mL) were harvested at various time points,
fixed, stained with PI, and analyzed by flow cytometry.  The percentage of cells with
DNA content greater than 4C was plotted as a function of time.
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expected, the steady-state levels of pRb is reduced in E7 expressing PHKs and RPE1
cells (Figure 3.2B).  To examine the incidence of polyploidization over an extended
period of time, wild-type and E7-expressing RPE1 cells were serially passaged for longer
than one month and stained with PI as described (Materials and Methods) and analyzed
by FACS for DNA content. The RPE1 cells were used for this experiment, because PHKs
cannot be cultured for more than a few passages.  Figure 3.2C shows that there was a
small but statistically significant increase (p < 0.001) in the percentage of polyploid cells
in the Rb-downregulated RPE1-E7 cells (0.67% ± 0.13%) compared to the RPE1-vector
control cells (0.43% ± 0.11%).
Although Rb-/- MEFs have a higher incidence of spontaneous polyploidization
than E7-expressing RPE1 cells, these differences can be attributed to several factors.  In
MEFs, which as primary cells tend to acquire more mutations in culture, the Rb
downregulation is not as complete in E7 transfected RPE1 cells as it is in Rb-/- MEFs.
Also, E7 has been shown to have Rb-independent biological activities (Munger et al,
2001), such as interactions with cell cycle regulators such as p21, p27, and cdc25A,
which may cause other effects on the cell (Funk et al, 1997; Katich et al, 2001; Zerfass-
Thome et al, 1996).
It has previously been thought that prolonged activation of the spindle assembly
checkpoint is necessary for the mechanism that leads to polyploidy.  The low incidence
of spontaneous polyploidy may have been because untreated cells trigger the spindle
assembly checkpoint only during rare spontaneous events.  In order to increase the
frequency with which the cells have prolonged activation of the spindle assembly
checkpoint, the microtubule depolymerizing drug nocodazole was used. After treating
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with nocodazole, E7-expressing PHKs and RPE1 cells showed a significant increase in
polyploidy compared to vector controls (42.9% vs 10.0% in PHKs and 42.0% vs 1.0% in
RPE1 cells, Figure 3.2D).  Time course analysis of polyploidization indicates that the
increase in polyploidy in RPE1-E7 cells begins approximately 40 hours after nocodazole
treatment (Figure 3.2E).  To investigate to what extent this result is specific to
nocodazole, the drug Monastrol, a small molecule inhibitor of the mitotic kinesin motor
protein Eg5, which triggers the spindle assembly checkpoint through formation of
monopolar spindles, was used.  The RPE1-E7 cells also showed an increase in polyploidy
(39.9% vs 4.5%) in response to Monastrol (Figure 3.2D).
Rb downregulation does not effect the spindle assembly checkpoint or mitosis.  A
number of studies have proposed that downregulation of Rb contributes to loss of spindle
assembly checkpoint control and that this may be a mechanism for polyploidization
(Hernando et al, 2004; Patel et al, 2004; Thomas & Laimins, 1998).  On the other hand,
Hernando et al (2004) suggest that Rb-downregulation causes hyperactivation of the
spindle checkpoint through upregulation of MAD2 (Hernando et al, 2004).  However,
these contradictory studies did not examine the effect of Rb-downregulation on the
spindle assembly checkpoint directly, but rather used DNA content alone to examine the
cell cycle.  Here the effect of Rb on the checkpoint by using an antibody against the
mitotic marker phospho-histone H3 (P-his H3) that stains mitotic cells from prophase to
late telophase (Juan et al, 1998) was examined.  Concurrent staining with both the P-his
H3 antibody and PI allows differentiation between mitotic cells and interphase cells with
a 4C DNA content. A mitotic index curve was constructed by treating wild-type and Rb-/-
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MEFs with nocodazole and examining the percentage of mitotic cells with a 4C DNA
content.  By staining the cells at various time points, the percentage of cells in mitosis
over time was determined.  This allowed for differentiation between spindle assembly
checkpoint activation and abrogation.  When the cells halt in mitosis, the percentage of
cells positive for P-His H3 increases.  As the cells adapt to the spindle assembly
checkpoint, the percentage of cells positive for P-His H3 decreases.  If the spindle
assembly checkpoint were abrogated by downregulation of Rb, the percentage of cells in
mitosis are expected to be significantly lower than in the control cells.
Figure 3.3A shows that the mitotic index curves for wild-type MEFs and Rb-/-
MEFs are not significantly different.  The percentage of cells halted in mitosis is
relatively low in MEFs most likely because the cells do not grow very well.  Therefore, in
order to obtain larger numbers of cells in mitosis and to examine the spindle assembly
checkpoint in human epithelial cells, mitotic index curves were also constructed for Rb-
downregulated RPE1 cells and PHKs.  Both of these cell types also showed no significant
difference from controls (Figure 3.3B and C).  Therefore the spindle assembly checkpoint
is functional in Rb-downregulated cells, which suggests that an alternate mechanism
leads to polyploidization in Rb-downregulated cells.
 Time-lapse videomicroscopy was also used to compare the length of normal
mitosis and cytokinesis for wild-type MEFs versus Rb-/- MEFs and RPE1-vector versus
RPE1-E7 cells. The duration of mitosis was measured as the time between nuclear
envelope breakdown (NEB) and nuclear envelope reformation (NER).  Table 3.1 shows
that the time spent in mitosis was not significantly different between wild-type MEFs and
Rb-/- MEFs (41 min ± 11 min vs. 44 min ± 15 min) or RPE1-vector and RPE1-E7 cells
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Figure 3.3.  Rb-downregulation does not affect the spindle assembly checkpoint.
Mitotic index of (A) wild-type and Rb-/- MEFs and (B) RPE1 cells and (C) PHKs
expressing vector or E7.  Cells under nocodazole treatment (50 ng/mL) were harvested at
various time points, fixed, stained with rat anti-phospho-histone H3 IgG2a and FITC-
conjugated anti-Rat IgG2a, stained with PI, and analyzed by flow cytometry.  The
percentage of cells positive for p-His H3 with a 4C DNA content was plotted as a
function of time.  Data represent the means of 2-3 determinants from a representative
experiment of 3.
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Table 3.1.  Rb-downregulation does not affect mitosis as determined by time-lapse
videomicroscopy.
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time-lapse videomicroscopy
n=56
n=17
128+3034+7
37+6 138+40
0.19 0.54
33+1641+11
44+15 45+27
0.40 0.01
74+17
89+38
0.03
96+28
102+39
0.66
Wildtype MEFs
Rb-/- MEFs
Mitosis + cytokinesis
	 (min)
Number of
cells
Mitosis
(min)
n=40
n=40
RPE1-vector
Cytokinesis
(min)
RPE1-E7
p-value
p-value
93
94
(34 min ± 7 min vs. 37 min ± 6 min).  These data are consistent with the mitotic index
curves in Figure 3.3, supporting the hypothesis that lack of Rb does not have a significant
effect on the duration of mitosis, an observation different from the previous study by
Hernando et al (2004) (Hernando et al, 2004).
In agreement with what was described by Hernando et al (2004), the current time-
lapse data show that Rb-/- MEFs did spend significantly more time completing cytokinesis
than wild-type MEFs (Hernando et al, 2004).  However, the cells did eventually cleave
into two daughter cells.  Therefore cleavage failure in response to spindle disruption does
not appear to be a mechanism for polyploidization.
Re-replication is not a significant source of polyploidy in Rb-downregulated cells.  It
has been proposed that Rb plays a role in preventing DNA re-replication (Lentini et al,
2002).  This possibility is directly tested here.  In the Rb-/- MEFs and both PHKs and
RPE1 cells expressing E7, cells exit mitosis approximately 16-20 hours after nocodazole
treatment (Figure 3.3), but a significant incidence of polyploidy is not seen until
approximately 40 hours after nocodazole treatment (Figure 3.2E).  These cells have a 4C
DNA content at mitosis yet do not show an 8C DNA content until 24 hours later.  The
kinetics of polyploidization in these Rb-downregulated cells suggest that re-replication of
DNA does not contribute to polyploidization.  Also, because re-replication is an
inefficient process, the result is usually aneuploidy where the cell cycle profile would not
have a discreet 8N peak, but rather a percentage of cells evenly spread out between 4N
and 8N.  The flow cytometric analysis has a discreet 8N peak, which suggests that the
cells efficiently replicated its DNA, not by the process of re-replication.
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In addition to this observation, we performed a mitotic shake-off experiment to
examine the potential contribution of re-replication to polyploidization in Rb-
downregulated cells.  Cells that have entered mitosis “round-up” and become tenuously
attached to the plate.  Although some cells in prophase may decondense their
chromosomes and return to interphase, the cells that are able to be shaken off the dish are
considered to be at “a point of no return” and are committed to entering mitosis (Rieder
& Cole, 1998).  The mitotic shake-off experiment shown in Figure 3.4 was performed by
first adding nocodazole to RPE1-vector or -E7-expressing cells.  After 20 hours of
nocodazole treatment, mitotic cells were shaken off and replated in nocodazole-
containing media (Figure 3.4A).  A majority of these shaken-off RPE1 cells (86%) were
confirmed by flow cytometry to be in mitosis.  With expression of E7, 39% of RPE1 cells
became polyploid compared to only 2.7% of vector controls (Figure 3.4B).  This
demonstrates that E7 expressing polyploid cells can arise from a mitotic cell.
In order to further clarify the role of re-replication in E7-expressing cells, an all
day mitotic shake-off experiment was also done.  Nocodazole was added to RPE1 vector
and E7 expressing cells, and starting 14 hours after treatment, mitotic cells were shaken
off and collected every hour until 22 hours post-nocodazole treatment.  All of the mitotic
cells were pooled together and counted, and the remaining non-mitotic cells were
trypsinized and counted.  Approximately 76% of vector and 82% of E7-expressing cells
entered mitosis during this 8 hour period.  Under these conditions, 35-40% of RPE1-E7
cells would become polyploid.  This suggests that many of these cells did enter mitosis
before becoming polyploid, however it does not completely rule out re-replication as a
mechanism to polyploidy.  This experiment was only done over 8 hours, and more cells
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Figure 3.4. Rb-downregulated mitotic cells are capable of polyploidy formation.
Asynchronous RPE1 cells expressing vector or E7 were treated with nocodazole (50
ng/mL).  A. After 20 hours of nocodazole treatment, cells were measured for p-His H3
expression and DNA content.  Cells positive for p-His H3 with a 4C DNA content are
indicated.  Mitotic cells were shaken-off and replated in nocodazole-containing medium
for an additional 52 hours.  B. Cells were analyzed for PI content.  Data from a
representative experiment (of 3) are shown.
Figure 3.4
20 hrs 72 hrs
Vector
E7
PI
Mitotic
Shake Off
Nocodazole
ph
os
ph
o-
his
to
ne
 H
3
2N 4N 8N
2N 4N 8N0 200 400 600 800 1000
100
101
102
103
104
0 200 400 600 800 1000
100
101
102
103
104
0
100
200
300
400
0
50
100
150
200
250
2.7%
39.1%
86.5%
86.4%
A B
97
98
may have continued to enter mitosis had the experiment been continued over a longer
period of time (i.e. 16-24 hours).  Also, an additional experiment that may help to further
dismiss re-replication as a mechanism to polyploidy includes another type of mitotic
shake-off experiment.  After serially removing shake-off cells over an 8-12 hour period,
the mitotic and non-mitotic cells would be stained with PI and analyzed by flow
cytometry.  If re-replication is not a major mechanism to polyploidization, we would
expect to see very few cells with 8N DNA content from the E7 expressing non-mitotic
cells.
Downregulation of Rb abrogates the postmitotic checkpoint. Next we tested whether
abrogation of the postmitotic checkpoint after adaptation to the spindle assembly
checkpoint contributes to polyploidization in Rb-downregulated cells.  A previous study
suggested that downregulation of Rb may facilitate DNA replication of cells with 4C
DNA content in a G1-like state (Khan & Wahl, 1998).  However, in this study, the cell
cycle state and pRb level of the control cells after adaptation to mitotic disruption was not
well characterized.  Also, direct evidence of DNA replication in Rb-downregulated cells
was not provided in this particular study. As a result, direct evidence of postmitotic
checkpoint abrogation in Rb-downregulated cells leading to polyploidization has not been
demonstrated.  In order to study this proposed mechanism in more detail we created a cell
population, confirmed it to be in a G1-like state, and examined the postmitotic checkpoint
with a BrdU incorporation assay.
We first treated RPE1-vector cells with nocodazole for 48 hours in order to
activate the spindle assembly checkpoint and obtain cells with 4C DNA content.  We
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then analyzed in which cell cycle stage these RPE1-vector cells were halted.  We
measured the protein expression levels of the G1 cyclin D1 and the G2 cyclin B and Rb
phosphorylation.  Figure 3.5A shows that in RPE1-vector cells, cyclin D1 was increased
approximately 2-fold, cyclin B was decreased approximately 4-fold, and pRb became
hypophosphorylated after nocodazole treatment. These results indicate that some of the
RPE1 cells are halted in a G1 cell cycle state two days after nocodazole treatment.
Next, the extent to which E7 expressing RPE1 cells are capable of replicating
DNA following adaptation to the spindle assembly checkpoint was tested.  We incubated
nocodazole-treated RPE1-vector and RPE1-E7 cells with BrdU and examined the ability
of the cells with 4C DNA content in a G1 state to incorporate BrdU after they adapted to
the spindle assembly checkpoint and exited mitosis. As shown in Figure 3.5B, 10% of
RPE1-E7 cells with DNA content >4C incorporated BrdU, whereas only 0.4% of vector
control cells with >4C DNA content incorporated BrdU.  These results suggest that Rb-
downregulation causes polyploidy in cells with 4C DNA content in a G1 state via
abrogation of the postmitotic checkpoint.
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Figure 3.5. Rb-downregulation in cells with a 4C DNA content in a G1-like state
results in replication. A. RPE1 cells arrest in a G1-like state after nocodazole (50
ng/mL) treatment.  Asynchronous cultures of RPE1-vector cells were incubated in
nocodazole containing medium for 48 hours.  Total protein extracts were resolved by
SDS-PAGE and blotted with antibodies against cyclin B, cyclin D1, pRb, and tubulin.  B.
RPE1-vector and E7 expressing cells were treated with nocodazole or DMSO for a total
of 72 hours.  At 70 hours post treatment, the cells were incubated for the remaining 2
hours with BrdU.  The ability of cells with 4C DNA content to incorporate BrdU was
examined.  BrdU positive cells with DNA content >4C are indicated.  Data from a
representative experiment (of 3) are shown.
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Discussion
This study explores the mechanism underlying the generation of polyploidy in
Rb-downregulated cells.  A number of possibilities was tested, and the data indicate that
Rb does not have an effect on the spindle assembly checkpoint or on the length of time
cells spent in mitosis.  This is in contrast to Hernando et al (2004) who suggest that Rb
downregulation and the subsequent effects on the Rb pathway, including upregulation of
Mad2, result in a hyperactive spindle checkpoint (Hernando et al, 2004), which has been
proposed to predispose cells to additional genomic instability.  This discrepancy may be
due to the interpretation of the time-lapse videomicroscopy results, which differs from
theirs. They measured the length of mitosis from prometaphase to late anaphase by
examining chromosome condensation and cell division (Hernando et al, 2004).  On the
other hand, I measured mitosis from NEB to NER, which are more distinctly defined and
easily seen parameters.  Also, in the previous study shRNA or expression of the oncogene
E1A was used to downregulate Rb, both of which may affect genes other than Rb (Helt &
Galloway, 2003; Hsieh et al, 2004; Kumar et al, 2003).  Instead, the experiments in this
study employed Rb-null MEFs, which completely lack any Rb, in addition to E7-
expressing cells.  A more recent study with Mad2 inducible upregulation demonstrates an
increase in polyploid cells and a link to chromosomal instability upon Mad2
overexpression (Sotillo et al, 2007).  However, cells overexpressing Mad2 do not appear
to be equivalent to Rb-downregulated cells, as Mad2 overexpression led to partial mitotic
block of proliferating cells, a phenomenon never seen in Rb-null cells.
The data also suggest that DNA re-replication is not a significant cause of
polyploidization in Rb-downregulated cells in response to microtubule disruption.
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Rather, I have shown that normal cells treated with low doses of nocodazole adapt to the
spindle assembly checkpoint and exit mitosis.  They then proceed into G1 with a 4C
DNA content where they are stopped at the postmitotic checkpoint. Rb-downregulated
cells proceed through this checkpoint, replicate their DNA, and become 8C.  Thus, these
results demonstrate that Rb is important for maintenance of the postmitotic checkpoint,
and that Rb-downregulated cells are able to proceed through this checkpoint, replicate
their DNA, and become polyploid.
This study used Western blot analysis of a minimal number of cell cycle markers,
including cyclin B, cyclin D1, and phosphorylated Rb, to demonstrate that the cells are in
a G1-like state.  In order to more fully determine the cell cycle state that RPE1 cells are
in after prolonged nocodazole treatment, a more detailed analysis of cell cycle markers
may be used.  Other cyclins may be checked including the G1/S phase transition cyclin E,
the mitotic cyclin A, and the other G1 cyclins D2 and D3.  A better test of cell cycle state
would also be to perform kinase assays on the cdks associated with particular cyclins at
various stages of the cell cycle.  For example, if cells are in a G1-like state and Rb is
hypophosphorylated, cdk2, 4, and 6 activity when associated with cyclin D should be
decreased.  In fact, it would be useful to analyze the cell cycle state and kinase activity at
various time points after addition of nocodazole in both RPE1 and PHKs with or without
E7 expression to study the kinetics of cell cycle proteins during nocodazole treatment.
As previously suggested and as the data here indicate, the postmitotic checkpoint
is Rb-dependent (Lanni & Jacks, 1998).  However, p53 also appears to play a key role in
mediating the postmitotic checkpoint (Andreassen et al, 2001; Di Leonardo et al, 1997;
Lanni & Jacks, 1998) and p21 is responsible for at least part of this p53-mediated
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postmitotic arrest (Khan & Wahl, 1998; Lanni & Jacks, 1998; Stewart et al, 1999). The
cdk inhibitor p21 binds to and inactivates cyclin/cdk complexes including cyclinE1/cdk2
and cyclinA2/cdk2, resulting in pRb hypophosphorylation that inhibits E2F activity and
arrests the cell cycle at the G1/S transition (Stewart & Pietenpol, 2001; Vogelstein et al,
2000).  Our lab has previously shown that p53 levels are not downregulated in E7
expressing cells.  However, with pRb already down-regulated, the primary target of p53
and p21 at this checkpoint does not exist.  Therefore polyploidization can occur in Rb-
downregulated cells in the presence of an intact p53/p21 pathway.
This study has important implications for cancer in general, and for cervical
cancer in particular, because of the results with the HPV oncogene E7.  HPV E6 and E7
are the oncogenes necessary for transformation in high-risk HPVs, which are associated
with cervical lesions that eventually may lead to cervical carcinomas.  Although E6 and
E7 are able to immortalize primary human epithelial cells, they are not sufficient to
induce transformation of human cells (Fan & Chen, 2004).  Instead, it is believed that
genomic instability caused by E6 and E7 predisposes the cells to accumulate additional
genomic aberrations necessary for malignant transformation (Duensing et al, 2000;
Duensing & Munger, 2002b).  As shown here and in other studies, HPV-E7 expressing
cells are able to become polyploid (Patel et al, 2004; Thomas & Laimins, 1998;
Thompson et al, 1997).  Also, Olaharski et al (2006) concluded that polyploidy and
chromosomal instability are related events that predispose cells to aneuploidy and
subsequently to malignancy (Olaharski et al, 2006).  The finding here that Rb-
downregulation results in polyploidization through abrogation of the postmitotic
checkpoint has important implications for cancer prevention and/or treatment.
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Understanding this mechanism of polyploidization will be useful in developing therapies
against its accumulation in Rb-downregulated, untransformed cells in order to prevent
accumulation of additional genomic aberrations that could lead to carcinogenesis.
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CHAPTER IV
CONCLUSIONS
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The first half of this dissertation examined the effect of Cbfb/MYH11 on
leukemogenesis in the presence or absence of a wild-type Cbfb allele.  In this study,
transgenic mice that express the fusion gene Cbfb/MYH11 on one allele and are Cbfb null
for the second allele were created.  These mice develop leukemia with a significantly
shorter latency than those Cbfb/MYH11 mice that retain a copy of wild-type Cbfb.  Both
genotypes of mice present with all of the characteristics of myeloid leukemia, including
an increase in white blood cells, a decrease in red blood cells (anemia), and infiltration of
the bone marrow, spleen and liver.  Most importantly, flow cytometry analysis of
peripheral blood from Cbfb+/MYH11 and Cbfb-/MYYH11 leukemic mice shows a block in the
differentiation of hematopoietic cells including decreases in the percentages of
granulocytes, macrophages, T-cells, and B-cells and an increase in the percentage of c-
kit+ progenitor cells.
Pre-leukemic analysis of the bone marrow cells from both Cbfb/MYH11-
expressing mice supports a block in differentiation as well.  Flow cytometry analysis of
these pre-leukemic cells shows an increase in the number of hematopoietic stem cells,
and also an increase in myeloid progenitor cells. These progenitor cells show immuno-
phenotypic characteristics of MEPs, but the peripheral blood smears show cells with
myelo-, mono-, and erythro-blast morphologies, and the in vitro assay confirms that these
progenitors have the differentiation capacity of CMPs—they are able to form BFU-E,
CFU-GM, and CFU-GEMM colonies.  These cells look similar to the population
previously shown by Kuo et al (2006) called abnormal myeloid progenitors (AMPs) (Kuo
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et al, 2006).  These AMP-like cells are the precursors that will expand into the fully
transformed leukemic cells.
Leukemia, simply, is caused by both a block in differentiation of hematopoietic
cells and an increase in proliferation of these cells.  The fusion protein Cbfβ-SMMHC
causes a partial block in differentiation, and it is theorized that a second, cooperating
mutation conveying a proliferative advantage is needed for full transformation.  In
general, mice acquire random genetic mutations over time.  Subsequently, after a long
enough period of time, mice with expression of Cbfb/MYH11 may acquire a genetic
mutation in a gene that provides a proliferative advantage to the cell.  This cell expands
to cause leukemia from a clonal population of transformed cells. Because the Mx1;Cre
system is “leaky” there is some minimal expression of the fusion gene without induction
by pIpC.  This event is sufficient to cause expansion of cells containing Cbfb/MYH11 and
a null Cbfb.  In this study, there was a significantly shorter latency in Cbfb/MYH11 mice
without wild-type Cbfb compared to those mice expressing it.
The short latency in the Cbfb-/MYH11 mice suggests one of two possible scenarios.
The first is that there are no acquired mutations because there has not been adequate time
in which to attain them.  In this case, the two mutations are sufficient-- the presence of
Cbfb/MYH11 causes a block in differentiation and the lack of Cbfb creates a dominant
effect, not just inhibiting normal hematopoiesis, but also adding a transforming effect to
this expanding progenitor cell population.  This possibility could be analyzed using a
conditional Cbfb-/- mouse.  Normally Cbfb-/- mice are embryonic lethal due to a lack of
definitive hematopoiesis as was seen in the Cbfb/MYH11 heterozygous mice.  Creation of
a conditional Cbfb knock-out mouse model would allow normal development to
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adulthood with both Cbfb alleles expressed but flanked by Lox-P sites.  These mice
would be crossed with Mx1;Cre mice, and the second Cbfb allele could be deleted in
adulthood.  First, these mice could be monitored for onset of leukemia, in order to
determine if the lack of wild-type Cbfb is sufficient for leukemogenesis.  Our previous
studies suggest that Cbfb/MYH11 is necessary for transformation, although it is possible
that the lack of Cbfb may induce a myeloproliferative disease instead of cancer.  My
experiments and those from Kuo et al (2005) show that it is the presence of the fusion
gene that dictates the phenotype of the leukemia.  If these Cbfb-/- mice fail to develop
leukemia, or if they develop leukemia with a long latency, the Cbfb-MYH11 fusion gene
could be introduced by retroviral infection to bone marrow from these mice and then
injected into wild-type irradiated recipients.  This approach would result in mice whose
bone marrow cells contained the fusion protein, but no copies of wild-type Cbfb.  These
mice would then also be monitored for onset of leukemia.  These mice would be expected
to become leukemic, because this genotype essentially recapitulates that of the Cbfb-
/MYH11 mice.  However, experiments with the conditional Cbfb knock-out mice could be
used to address questions about the latency of leukemia between the two mouse models.
These mice could also be used to test whether the temporal occurrence of the two
mutations is important.
  The second possible explanation for the short latency in the Cbfb-/MYH11 mice
is that the complete block in differentiation caused by both the presence of Cbfb/MYH11
and the lack of wild-type Cbfb causes a dramatic expansion in the progenitor population
that significantly increases the likelihood and decreases the latency of the occurrence of
additional mutations.  It has generally been observed that cells that differentiate no longer
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proliferate and vice versa.  Therefore it has been suggested that decreased differentiation
may act as a proliferative stimulus (Cao et al, 1997) or that there will at least be some
compensatory increase in the number of progenitor cells from a decrease in
differentiation (Kundu & Liu, 2003).  In the Cbfb-/MYH11 mice, the increase in progenitor
cells most likely provides a larger more susceptible pool of cells that are prone to
acquiring proliferative mutations.  The full block in differentiation from both Cbfb
mutations may cause acceleration of this natural acquisition of genetic mutations.
Potential proliferative mutations include those that are able to induce S-phase
progression.  One study showed that mice with bone marrow cells expressing both CBFβ-
SMMHC and the HPV-16 E7 oncogene developed leukemia faster than those mice with
only CBFβ-SMMHC.  In these cells, E7 binds to and degrades Rb so that the E2F
transcription factors are free to activate S-phase proteins.  This significantly increases the
rate of proliferation in these cells under normal conditions and under certain mitotic
stresses.  The latter half of this dissertation explores the possible mechanisms through
which E7 is able to cause cell cycle progression and subsequently polyploidization.
Affecting 6% of women worldwide, cervical cancer is one of the most common
cancers in the world (Parkin et al, 2001).  Although there is now a prophylactic vaccine
for the two most common high-risk types of HPV, cervical cancer research must continue
because the vaccine does not affect currently infected individuals or the immuno-
compromised, nor does it prevent all types of HPV infection.
Although a high-risk HPV genome is present in greater than 99% of cervical
cancer cases, this does not necessarily induce nor guarantee transformation.  Only a
fraction of high-risk HPV infected cells become cancerous, and it often occurs after a
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significant latency.  This suggests that HPV is not sufficient for transformation, but that
the virus (and presumably its oncogenes) predisposes the infected cells to accumulate
additional genomic mutations that will then lead to cancer.
It has previously been shown that while the HPV oncogene E7 is able to
immortalize cells, it is not sufficient for transformation.  However E7 has been shown to
induce genomic instability, a precursor to polyploidy. While the genetic mutations that
cause polyploidy may not be sufficient for transformation alone, the accumulation of
polyploid cells results in aneuploidy, and genomic instability, which increases the
probability of acquiring additional mutations (Duensing et al, 2000; Duensing & Munger,
2002b).  In the case of HPV E7, once these numerical alterations occur, continued
expression of the oncogene is still necessary to maintain transformation (Doorbar 2006).
The method by which E7 induces polyploidy may be used to develop therapies against
induction of cervical cancer.  Several conflicting mechanisms to polyploidization have
been suggested for E7 expressing, Rb-downregulated cells.  This study explored each of
these proposals in order to better understand how polyploidization occurs in these cells.
This study shows that Rb-downregulation does not play a role in mitosis, either
under normal conditions or upon microtubule disruption.  Although Rb may play some
role in cytokinesis as seen with the increased length of cytokinesis in the time-lapse data,
the downregulation of Rb did not prevent abscission from occurring.  The time-lapse
videomicroscopy also did not show the presence of any fused cells.  Because cellular
fusion usually occurs with viral infection, it may require additional viral proteins besides
E7.
112
Re-replication is a process where the cell completes S-phase replication and fails
to enter or complete mitosis before replicating the DNA again.  It may also be described
as the process where DNA is replicated two or more times without completed cell
division.  However, the preferred definition makes the distinction that re-replication does
not occur if the cells have at least entered mitosis, even if it is not completed.  Therefore,
this study shows that Rb-downregulated cells do enter mitosis, although the process is not
completed before the cells re-enter S-phase.
Instead, after cells fail to complete mitosis due to microtubule disruption, they
proceed into a G1-like state as determined by protein expression levels of cyclins and
phosphorylated Rb.  However, in this case wild-type cells have a 4N DNA content and
are normally arrested in this state.  The precise trigger for this post-mitotic checkpoint
remains unknown, but it seems logical for the cell to have a checkpoint that protects
against replication of 4N cells, which could lead to proliferation of polyploid cells.  In
HPV-16 E7 expressing cells, E7 binds to and causes degradation of Rb, which releases
the E2F transcription factors to activate S-phase proteins.  Thus, E7-expressing, Rb-
downregulated cells replicate their 4N genomes leading to 8C polyploid cells.
These findings in Rb-/- MEFs and Rb-downregulated cells would suggest that
HPV-E7 abrogation of the postmitotic checkpoint is Rb-dependent.  However, E7 does
have Rb-independent activities, including inhibiting the activity of p21 and p27 (Funk et
al, 1997; Jones et al, 1997; Zerfass-Thome et al, 1996) which affect their cognate
cdk/cyclin complexes and may also abrogate cell cycle checkpoints in G1, S, and mitosis.
In order to determine whether abrogation of the postmitotic checkpoint by HPV-E7 is
Rb-dependent, mutation studies involving E7 mutants deficient for degradation and/or
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binding of Rb will be necessary.  There are several known mutants that may be useful.
Mutants Δ6-10, L67R, and LL82-83RR, retain binding to Rb but do not induce
degradation.  Mutants C24G, Δ21-24, and E26G neither bind nor degrade Rb.  Based on
the results of this study, it may be hypothesized that abrogation of the postmitotic
checkpoint is an Rb-dependent activity of E7.  Many of these E7 mutants are also
defective for other E7 activities including inhibition of p21 and p27, and activation of
cdc25A.  Assessing the ability of these mutants to become polyploid upon microtubule
disruption, will determine the importance of these other E7 functions in abrogation of the
post-mitotic checkpoint and polyplpoidization.
E7 induced polyploidization should also be studied in the context of both E6 and
the entire HPV genome.  Expression of HPV-16 E6 also causes abrogation of the post-
mitotic checkpoint upon microtubule disruption, and combined expression of E6 and E7
leads to an increase in the number of polyploid cells in a population (Liu et al, 2007).
Therefore, expression of not just E7 but also the entire HPV genome may also lead to an
increase in polyploidization.  However, E2 has been shown to negatively regulate E7,
which may cause a decrease in polyploidy.  Also, E4 has recently been shown to increase
re-replication (Knight et al, 2004), which may also lead to polyploidy and result in an
increase in polyploid cells upon expression of the HPV genome.
Both of the studies presented in this dissertation examine the role of a
chromosomal abnormality in carcinogenesis.  The structural chromosomal aberration
Cbfb/MYH11 is necessary but not sufficient for leukemogenesis.  However, the lack of
wild-type Cbfb in these cells leads to the accumulation of cooperating mutations and
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subsequently AML.  The protein E7 is also insufficient for transformation in HPV
positive cells.  However, the expression of E7 does result in polyploidization, a numerical
chromosomal aberration that leads to aneuploidy and carcinogenesis through
accumulation of additional genetic mutations.
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